Combination therapy comprising GDC-6036 and GDC-0077 for the treatment of cancer
By combining the KRasG12C inhibitor GDC-6036 with the PI3K inhibitor inalipse, the inadequacy of treatment for KRasG12C-mutant cancers has been addressed, achieving effective suppression of KRasG12C-positive tumors and prolonging survival.
Patent Information
- Application Number
- CN202380032303.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-06
- Filing Date
- 2023-04-04
- Publication Date
- 2024-11-22
AI Technical Summary
Current treatments have limited effectiveness against cancers such as lung cancer, colorectal cancer, and pancreatic cancer carrying the KRasG12C mutation, and there is a lack of effective therapies. In particular, for patients with KRasG12C-positive tumors carrying the KRasG12C mutation, current treatment options are limited and the prognosis is poor.
A combination therapy is provided, comprising the combined use of the KRasG12C inhibitor GDC-6036 and the PI3K inhibitor inalipse, to treat KRasG12C mutation-mediated cancers, including lung cancer, colorectal cancer, and pancreatic cancer, by oral administration of an effective amount of the drugs according to a specific dosing regimen.
It significantly inhibits cancer cell growth, reduces tumor volume, prolongs patient survival, improves quality of life, reduces treatment side effects, and provides an effective treatment option that does not require prior testing for the presence of PI3KCA mutations.
Smart Images

Figure BDA0005069346010000041 
Figure BDA0005069346010000051 
Figure BDA0005069346010000091
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 328,149, filed on April 6, 2022, which is incorporated herein in its entirety and for all purposes. Technical Field
[0003] This article provides information on KRas G12C Combination therapies of inhibitors (e.g., GDC-6036) and PI3K inhibitors (GDC-0077, inavolisib) and methods of using such combination therapies. Background Art
[0004] Kirsten rat sarcoma viral oncogene homolog (KRAS) is a core component of the RAS / MAPK signaling pathway, an intracellular protein network that transmits extracellular growth factor signals to regulate cell proliferation, differentiation, and survival. Mutations in KRAS can result in changes to several amino acids, including glycine 12 (G12), glycine 13, and glutamine 61, and are commonly found in solid tumors and are associated with tumorigenesis and aggressive tumor growth. Oncogenic KRAS mutations that result in a change from G12 to cysteine (G12C) are prevalent in non-small cell lung cancer (NSCLC) (~12%), colorectal cancer (CRC) (~4%), and other tumor types (≤4%).
[0005] Carrying KRas G12C Advanced tumors with mutations (hereafter referred to as KRas G12C Positive tumors), including, for example, lung cancer (e.g., NSCLC), CRC, and pancreatic cancer, are incurable and have a poor prognosis. G12C Patients with positive cancers may have limited benefit from selective chemotherapy and targeted therapies, thus limiting the effective available treatment options.
[0006] Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that regulates cell proliferation, survival, and migration after activation by growth factor receptors and integrins. PI3K catalyzes the cleavage of phosphatidylinositol-4,5-bisphosphate (PIP 2 ) to produce phosphatidylinositol-3,4,5-triphosphate (PIP 3 ), which is a second messenger involved in the phosphorylation of AKT and other components of the AKT / mTOR pathway. Up to 70% of breast cancers have some form of molecular aberration of the PI3K / AKT / mTOR pathway. Activating mutations of PIK3CA (encoding the p110α subunit of PI3K) are highly prevalent in breast cancer and solid tumor malignancies.
[0007] Although PI3Kα inhibitors are either approved or in clinical development for the treatment of patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer harboring PIK3CA mutations, there remains a need for effective therapies and combination therapies for patients with KRas G12C Mutations in cancers such as lung, colorectal and pancreatic cancers. Summary of the invention
[0008] Provided herein are solutions to these and other problems in the art.
[0009] In one aspect, provided herein is a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof as described herein and inaricep or a pharmaceutically acceptable salt thereof.
[0010] In another aspect, a method for treating a patient suffering from KRas G12C A method for treating such lung cancer in patients with mutation-mediated lung cancer, the method comprising administering an effective amount of a combination therapy comprising: administering an effective amount of GDC-6036 or a pharmaceutically acceptable salt thereof QD according to a dosing regimen comprising one or more cycles and administering an effective amount of inaricep or a pharmaceutically acceptable salt thereof as described herein QD according to a dosing regimen comprising one or more cycles. In one such embodiment, the dosing regimen comprises 21 days or 28 days.
[0011] In another aspect, a method for treating a patient suffering from KRas G12C A method for treating such cancer in patients with mutation-mediated lung cancer, the method comprising administering an effective amount of a combination therapy comprising: GDC-6036 or a pharmaceutically acceptable salt thereof as described herein, administered QD according to a dosing regimen comprising one or more 21-day cycles, and an effective amount of inaricep or a pharmaceutically acceptable salt thereof as described herein, administered QD according to a dosing regimen comprising one or more 21-day cycles.
[0012] In another aspect, a method for treating a patient suffering from KRas G12C A method for treating such cancer in patients with mutation-mediated solid tumors, the method comprising administering an effective amount of a combination therapy comprising: GDC-6036 or a pharmaceutically acceptable salt thereof as described herein, administered QD according to a dosing regimen comprising one or more cycles as described herein, and an effective amount of inaricep or a pharmaceutically acceptable salt thereof as described herein, administered QD according to a dosing regimen comprising one or more cycles as described herein.
[0013] In another aspect, a method for treating a patient with a KRas G12CA method for treating a cancer of the type in a patient with a tissue-uncertain cancer with a suspected diagnosis of such a cancer, the method comprising: (i) determining the absence or presence of a KRasG12C mutation in a sample taken from a patient with a suspected diagnosis of cancer; and (ii) where the patient sample comprises a KRasG12C mutation, administering an effective amount of a combination therapy comprising: (a) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen comprising one or more cycles as described herein; and (b) inaricep or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen comprising one or more cycles as described herein.
[0014] In another aspect, provided herein is a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep or a pharmaceutically acceptable salt thereof for use in treating lung cancer, CRC or pancreatic cancer as described herein.
[0015] In another aspect, provided herein is a use of a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of lung cancer, CRC or pancreatic cancer.
[0016] In embodiments of the methods and uses described herein, administration of inaricep (GDC-0077) does not require prior testing or assessment for the presence of one or more PI3KCA mutations. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 Fitted tumor volumes for treatment with GDC-6036 alone, GDC-0077 alone, or the combination of GDC-6036 and inaricep are depicted. NCI-H2122 was less sensitive to KRAS-G12C inhibition; the maximum effect was stasis. GDC-6036 alone: TGI = 93%; GDC-0077 alone: TGI = 74%; combination: TGI = 113%.
[0018] Figure 2 Body weight changes are depicted for administration of GDC-6036 alone, GDC-0077 alone, or the combination of GDC-6036 and inaricep. All treatments were well tolerated.
[0019] 3A to 3H Depicted is the synergistic effect of the combination of GDC-6036+GDC-0077 on various NSCLC KRas G12C mutant cell lines. Figure 3A =H23P; Figure 3B =YSE410; Figure 3C =H1792; Figure 3D =H2122; Figure 3E =HOP62; Figure 3F=H2030; Figure 3G =HCC4017; and Figure 3H =HCC4019).
[0020] Figure 4 Depicted are fitted tumor volumes for treatment with GDC-6036 alone, GDC-0077 alone, or the combination of GDC-6036 and inaricep in the CR5048 CRC xenograft model.
[0021] FIG. 5A to FIG. 5C Depicted is the synergistic effect of the combination of GDC-6036+GDC-0077 on various CRC KRas G12C mutant cell lines. Figure 5A =SW1463; Figure 5B =SW837; and Figure 5C =HCC1263). DETAILED DESCRIPTION
[0022] definition
[0023] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. See, for example: Singleton et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 2nd edition, J. Wiley & Sons (New York, NY 1994); Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, Cold Springs Harbor Press (Cold Springs Harbor, NY 1989). Methods, devices and materials similar or equivalent to any method, device and material described herein can be used in the practice of the present invention.
[0024] The following definitions are provided to facilitate understanding of certain terms frequently used herein and are not intended to limit the scope of the present disclosure.All references cited herein are incorporated by reference in their entirety.
[0025] As used herein, unless otherwise indicated, the terms "about" and "approximately" when referring to the dosage, amount or weight percentage of the ingredients of the composition or dosage form, mean a dosage, amount or weight percentage recognized by those of ordinary skill in the art that provides a pharmacological effect equivalent to that obtained by the specified dosage, amount or weight percentage. The equivalent dosage, amount or weight percentage may be within the range of 30%, 20%, 15%, 10%, 5%, 1% or less of the specified dosage, amount or weight percentage.
[0026] As used herein, "KRasG12C “Inhibitor” refers to a covalent inhibitor that specifically binds to a mutant KRas protein comprising a Gly to Cys mutation at the position corresponding to residue 12.
[0027] "GDC-6036" refers to a compound having the following structure:
[0028]
[0029] It has the following chemical name: 1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one. In one embodiment, GDC-6036 is an adipate salt.
[0030] Inaricep, CAS Reg. No. 2060571-02-8, Genentech, USA 9650393; named as (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine -9-yl)amino)propionamide refers to a compound having the following structure:
[0031]
[0032] It has the chemical name (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide. Inaricep is also known as GDC-0077, RG6114, or RO7113755.
[0033] Inarliside is a potent, orally bioavailable, clinical-stage, selective inhibitor of the class I PI3K alpha isoform (PI3Kα) with >300-fold reduced potency for biochemical inhibition of other class I PI3Kβ, PI3Kδ, and PI3Kγ isoforms, and increased potency in tumor cells carrying mutant PI3K compared to wild-type (WT) PI3K cells (Braun, M. et al. "Discovery of GDC-0077: A highly selective inhibitor of PI3K-alpha that induces degradation of mutant-p110 alpha protein" Abstracts of Papers, 254th ACS National Meeting & Exposition, Washington, DC, USA, August 20-24, 2017, MEDI-22; Garland, K. et al. "Discovery of novel class of alpha selective PI3K inhibitors" Abstracts of Papers, 254th ACS National Meeting & Exposition, Washington, DC, USA, August 20-24, 2017, MEDI-22; Meeting&Exposition, Washington, DC, USA, August 20-24, 2017, MEDI-103; Hong, R. et al. "GDC-0077 is a selective PI3K alphainhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies" 2017 San Antonio Breast Cancer Symposium, December 5-9, 2017, San Antonio, TX, Abstract Publication Number: PD4-14; Edgar, K. et al. “Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development” Cancer Research 77 (13 Suppl): Abstract 156 July 2017).
[0034] GDC-0077 exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the membrane-bound 4,5-phosphatidylinositol bisphosphate (PIP 2 ) is phosphorylated to 3,4,5-phosphatidylinositol triphosphate (PIP 3 ). Inhibition of PIP 2 Phosphorylation to PIP 3 It reduces the downstream activation of AKT and pS6, leading to reduced cell proliferation, metabolism and angiogenesis. Nonclinical studies have shown that GDC-0077 specifically degrades mutant p110α, inhibits the proliferation of PIK3CA mutant breast cancer cell lines and induces apoptosis, inhibits tumor growth in human breast cancer xenograft models carrying PIK3CA mutations, and reduces downstream PI3K pathway markers (including the phosphorylated form of protein kinase B (pAKT), PRAS40 phosphorylated at threonine 246 (pPRAS40), and S6RP phosphorylated at serine 235 / 236 (pS6RP)).
[0035] The term "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce adverse, allergic or other untoward reactions when administered to animals such as, for example, humans, as appropriate.
[0036] The compound of the present invention can be in the form of a salt, such as a pharmaceutical salt." Pharmaceutical salt " includes both acid addition salts and base addition salts." Pharmaceutical acid addition salt " refers to those salts formed with inorganic acids and organic acids, the salt retains the biological effectiveness and properties of the free alkali, and is not unexpected biologically or otherwise, the inorganic acid is such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, etc., the organic acid can be selected from aliphatic, alicyclic, aromatic, aromatic aliphatic, heterocyclic, carboxylic acid and sulfonic acid organic acids, such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, dihydronaphthoic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc. In one embodiment, the salt is formed by adipic acid.
[0037] The term "pharmaceutical base addition salt" includes salts derived from inorganic bases, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, etc. Specific base addition salts are ammonium salts, potassium salts, sodium salts, calcium salts and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, and substituted amines include naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, tromethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydraziniline, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Specific organic non-toxic bases include isopropylamine, diethylamine, ethanolamine, tromethamine, dicyclohexylamine, choline and caffeine.
[0038] In some embodiments, the salt is selected from hydrochloride, hydrobromide, trifluoroacetate, sulfate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methanesulfonate, p-toluenesulfonate, bisulfate, benzenesulfonate, ethanesulfonate, malonate, xinafoate, ascorbate, oleate, nicotinate, saccharin, adipate, formate, glycolate, palmitate, L-lactate, D-lactate, aspartate, malate, L-tartrate, D-tartrate, stearate, furoate (e.g., 2-furoate or 3-furoate), naphthalene disulfonate (naphthalene-1,5-disulfonate or naphthalene-1-(sulfonic acid)-5-sulfonate), ethanesulfonate (ethane-1,2-disulfonate). The salts of the compounds include benzoate, adipate, oxalate, malonate, toluenesulfonate (2-m-benzenesulfonate), naphthalenesulfonate (2-naphthalenesulfonate), camphorsulfonate (camphor-10-sulfonate, e.g., (1S)-(+)-10-camphorsulfonate), glutamate, glutarate, hippurate (2-(benzamido)acetate), orotate, ditoluenesulfonate (p-xylene-2-sulfonate), and pamoate (2,2'-dihydroxy-1,1'-dinaphthomethane-3,3'-dicarboxylate).
[0039] The terms "inhibit" and "reduce", or any variation of these terms, include any measurable reduction or complete inhibition to achieve the desired result. For example, the activity can be reduced by about, up to about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more, or any range derivable therein, compared to normal.
[0040] The term "cancer" refers to a disease caused by the uncontrolled division of abnormal cells in a part of the body. In one embodiment, the cancer is lung cancer. In another embodiment, the cancer is non-small cell lung cancer (NSCLC). In another embodiment, the cancer is a solid tumor. In another embodiment, the cancer is colorectal cancer (e.g., metastatic CRC), breast cancer, or pancreatic cancer. As used herein, "cancer" refers to a disease characterized by the presence of KRas G12C Cancers characterized by mutations.
[0041] As used herein, "treatment" includes treatment with an effective amount of a therapeutic agent (e.g., GDC-6036 or inarliseb) or a combination of therapeutic agents (e.g., GDC-6036 or inarliseb). In one embodiment, treatment refers to treatment with an effective amount of GDC-6036 or a pharmaceutically acceptable salt thereof and inarliseb. Treatment may be first-line treatment (e.g., the patient may not have been treated before or has not received prior systemic therapy), or second-line or subsequent treatment. For example, if one or more symptoms associated with the cancer described herein are alleviated or eliminated, including but not limited to reducing cancer cell proliferation (or destroying cancer cells), alleviating symptoms caused by the disease, improving the quality of life of patients suffering from the disease, reducing the dose of other drugs required to treat the disease, and / or prolonging the patient's survival, the patient is successfully "treated".
[0042] The term "delaying progression" of a disease means postponing, hindering, slowing, slowing, stabilizing and / or slowing the progression of a cancer as described herein. Such a delay may be of varying lengths of time, depending on the history of the cancer as described herein and / or the patient being treated. It will be apparent to one skilled in the art that a substantial or significant delay may actually encompass prevention, in that the patient will not develop the cancer.
[0043] Herein, "effective amount" refers to the amount of therapeutic agents described herein (e.g., GDC-6036 and / or inarliseb) to achieve a therapeutic effect. In some instances, the effective amount of a therapeutic agent or a combination of therapeutic agents is the amount of an agent or a combination of agents that reaches a clinical endpoint provided herein. In one embodiment, an effective amount refers to the amount of GDC-6036 or a pharmaceutically acceptable salt thereof and the amount of inarliseb. The effective amount herein may vary according to factors such as the patient's disease state, age, sex, and weight, and the ability of the agent to cause an expected response in the patient. The effective amount is also the amount in which the beneficial effects of treatment exceed any toxic or deleterious effects of treatment. In some embodiments, an effective amount of a drug may have the following effects: reducing the number of cancer cells; reducing tumor size; inhibiting (i.e., slowing down or stopping) the infiltration of cancer cells into surrounding organs; inhibiting (i.e., slowing down or stopping) tumor metastasis; inhibiting (i.e., slowing down or stopping) tumor growth; and / or alleviating one or more of the symptoms associated with the disease. The effective amount may be administered once or multiple times. The effective amount of a drug, compound, pharmaceutical composition, or combination therapy described herein may be an amount sufficient to treat directly or indirectly.
[0044] “Objective response rate” or “ORR” is the percentage of patients who had a confirmed complete response or partial response as determined by the investigator according to RECIST v1.1 within two consecutive periods of ≥4 weeks.
[0045] “Duration of response” or “DOR” is the time from the first documented objective response to disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1.
[0046] “Progression-free survival” or “PFS” is the time from enrollment to the date of the first documented disease progression or death from any cause, whichever occurs first, as determined by the investigator according to RECIST v1.1.
[0047] As used herein, "complete remission" and "CR" refer to the disappearance of all target lesions and, if applicable, normalization of tumor marker levels.
[0048] As used herein, "partial response" and "PR" refer to the persistence of one or more non-target lesions and / or (if applicable) the maintenance of tumor marker levels above normal limits. PR may also refer to a decrease of ≥30% in the sum of the diameters of target lesions, the appearance of new lesions in the absence of CR, and clear progression of non-target lesions.
[0049] "Administration period" or "cycle" refers to a time period including the administration of one or more agents described herein (e.g., GDC-6036 and inaricep) and optionally not including the time period of the administration of one or more agents described herein. For example, a cycle may be a total of 21 days, and includes the administration of one or more agents described herein (e.g., GDC-6036 and inaricep) on each day of the cycle. In another example, the total duration of a cycle may be 28 days, and includes the administration of one or more agents described herein (e.g., GDC-6036 and inaricep) for 21 days and a 7-day rest period. "Rest period" refers to a time period in which at least one of the agents described herein (i.e., GDC-6036 and inaricep) is not administered. In one embodiment, the rest period refers to a time period in which any one of the agents described herein (i.e., GDC-6036 and inaricep) is not administered. The rest period as provided herein may include the administration of another agent that is not GDC-6036 or inaricep in some examples. In such cases, the administration of another agent during the rest period should not interfere with or impair the administration of the agents described herein. In one case, the cycle used herein refers to a 21-day cycle without a rest period. In another example, the total duration of a cycle can be 28 days and includes QD administration of one or more agents described herein (e.g., GDC-6036 and inaricep) on each day of the cycle.
[0050] A "dosing regimen" refers to an administration period as described herein that includes one or more cycles, wherein each cycle may include administration of an agent as described herein in different amounts at different times.
[0051] "QD" refers to once daily administration of an agent described herein.
[0052] "BID" refers to administration of an agent described herein twice daily.
[0053] "PO" refers to oral administration of an agent described herein.
[0054] "IV" refers to intravenous administration of any agent described herein.
[0055] Graded adverse events refer to severity grading levels determined by NCI CTCAE. In one embodiment, adverse events are graded according to the following table.
[0056]
[0057] The term "patient" refers to a human patient. The patient can be an adult.
[0058] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic products.
[0059] As used herein, "in combination with" means administering one therapeutic modality in addition to another therapeutic modality, e.g., a therapeutic regimen comprising administering inaricep and GDC-6036 or a pharmaceutically acceptable salt thereof as described herein. Thus, "in combination with" means administering one therapeutic modality before, during, or after the administration of another therapeutic modality to a patient.
[0060] A drug that is administered "concurrently" with one or more other drugs is administered within the same treatment cycle, on the same day of treatment with the one or more other drugs, and optionally at the same time as the one or more other drugs. For example, for a cancer treatment given every 3 weeks, the concurrently administered drugs are each administered on Day 1 of the 3-week cycle.
[0061] Combination therapy
[0062] Provided herein are combination therapies (compositions) comprising a KRas G12C inhibitors (eg, GDC-6036 or a pharmaceutically acceptable salt thereof (eg, GDC-6036 adipate)) and PI3K inhibitors (eg, inaricep).
[0063] In one aspect, provided herein is a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate) and inaricep. In one embodiment, the combination therapy described herein can be used to treat a disease comprising KRas G12C mutations in certain solid tumors.
[0064] In one embodiment, the combination therapies described herein can be used to treat a KRas G12C In one such embodiment, the lung cancer is a type of lung cancer that contains KRas G12C Mutations in non-small cell lung cancer (NSCLC).
[0065] In another embodiment, the combination therapies described herein can be used to treat other KRas G12C Mutated solid tumors. In one embodiment, the solid tumor is colorectal cancer, pancreatic cancer or breast cancer.
[0066] In one aspect, provided herein is a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen comprising one or more cycles and inarlised administered QD according to a dosing regimen comprising one or more cycles. In such embodiments, an assessment is made for the presence of mutant KRasG12C and the combination therapy described herein is administered only when a KRasG12C mutation is present. In one such embodiment, an assessment is not made for the presence of mutant PIK3CA.
[0067] In one embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more 21-day cycles, and inarliside or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more 21-day cycles. In one such embodiment, when the dosing regimen comprises one or more 21-day cycles, the dosing regimen comprises a rest period, wherein one or both of GDC-6036 and inarliside are not administered. In such embodiments, the combination therapy can be used to treat a patient comprising KRas as described herein. G12C Mutated solid tumors (eg, lung cancer). In one such embodiment, no assessment is performed for the presence of mutant PIK3CA.
[0068] In another embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more 28-day cycles, and inaricep or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more 28-day cycles. In such embodiments, the combination therapy can be used to treat a patient with a KRas serotype as described herein. G12C Mutated solid tumors (eg, lung cancer). In one such embodiment, no assessment is performed for the presence of mutant PIK3CA.
[0069] In one embodiment of the combination therapy described herein, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in a fixed dose QD administration form. In one embodiment, administration is by oral (PO), wherein GDC-6036 or a pharmaceutically acceptable salt thereof is formulated as a tablet or capsule. In one such embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is formulated as a film-coated tablet (and administered in this form).
[0070] In one embodiment of the combination therapies described herein, GDC-6036 or a pharmaceutically acceptable salt thereof is present in an amount of about 5 mg to 600 mg, 5 mg to 500 mg, 5 mg to 400 mg, 5 mg to 300 mg, 5 mg to 250 mg, 5 mg to 200 mg, 5 mg to 150 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 25 mg to 600 mg, 25 mg to 500 mg, 25 mg to 400 mg, 25 mg to 300 mg. In another embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg or 500 mg. In another embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg or 800 mg. In one such embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg or 400 mg. In one such embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 to 300 mg. In one such embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 200 mg. In one such embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 300 to 600 mg. In another such embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 400 mg. In a preferred embodiment, the GDC-6036 of the combination therapy described herein is administered in the form of an adipate. In such embodiments, the amount of GDC-6036 or a pharmaceutically acceptable salt thereof is administered relative to the amount of the free base form.
[0071] Including one or therapeutic agents in the combination therapy can change the efficacy and dosage of each agent in the dosing regimen. Therefore, in one embodiment, the amount of GDC-6036 or a pharmaceutically acceptable salt thereof is administered at a lower starting dose as described herein for the entire or partial cycle described herein. In one embodiment, GDC-6036 can be administered at a lower dose for at least 1, 2 or 3 days before increasing the dose. In one such embodiment, the amount of GDC-6036 or a pharmaceutically acceptable salt thereof is a 200 mg starting dose. In another such embodiment, the amount of GDC-6036 or a pharmaceutically acceptable salt thereof is a 300 mg starting dose. In such embodiments, the amount of GDC-6036 can be increased by 50 or 100 mg (e.g., 200 mg starting dose to 250 or 300 mg dose: 300 mg dose to 400 mg dose). In one embodiment, the starting dose of GDC-6036 is 200 mg, and the dose is increased to 400 mg.
[0072] In some embodiments, inarlised is administered in an amount of 3, 6 or 9 mg, for example, in the form of one or more oral tablets. In some embodiments, inarlised is administered orally in a 9 mg daily dose. In some of these embodiments, inarlised is administered orally in an amount of 9 mg, for example, in the form of oral tablets. In some embodiments, inarlised is administered orally in a 6 mg daily dose, for example, in the form of one or more oral tablets. In some of these embodiments, inarlised is administered in an amount of 3 mg, for example, in the form of oral tablets.
[0073] In one embodiment, inarlised as a component in the combination therapy described herein is administered in an amount of 6 mg QD with a dosing regimen that includes QD administration of each agent in a 21-day cycle. In another embodiment, inarlised as a component in the combination therapy described herein is administered in an amount of 9 mg QD with a dosing regimen that includes QD administration of each agent in a 21-day cycle. In another embodiment, inarlised as a component in the combination therapy described herein is administered in an amount of 3 mg QD with a dosing regimen that includes QD administration of each agent in a 21-day cycle. In one such embodiment, the amount of inarlised administered is reduced from the starting dose to 6 mg or 3 mg, as described herein.
[0074] In one embodiment, the amount of inaricep is less than the starting dose. In one such embodiment, the amount of inaricep is 6 mg. In one such embodiment, the amount of inaricep can be increased to 9 mg.
[0075] In one embodiment, the starting dose of GDC-6036 is 200 mg and the starting dose of inaricep is 6 mg. In another embodiment, the starting dose of GDC-6036 is 400 mg and the starting dose of inaricep is 6 mg. In yet another embodiment, the starting dose of GDC-6036 is 200 mg and the starting dose of inaricep is 9 mg.
[0076] In one embodiment, the combination therapy described herein is used to treat a patient comprising KRas G12C Mutated lung cancer. In one such embodiment, the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate) and inarlised, wherein both agents are administered according to a dosing regimen, and the dosing regimen includes QD administration of each agent in a 21-day cycle. In another such embodiment, the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate) and inarlised, wherein both agents are administered according to a dosing regimen, and the dosing regimen includes QD administration of each agent in a 28-day cycle. In such embodiments, lung cancer is non-small cell lung cancer (NSCLC). In another such embodiment, lung cancer is adenocarcinoma, squamous cell lung cancer, or large cell lung cancer. Lung cancer may be phase I or phase II lung cancer. In one embodiment, lung cancer is phase III or phase IV lung cancer.
[0077] In another embodiment, the invention can be used to treat a KRas G12C A combination therapy for lung cancer with a KRas mutation, wherein the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate), wherein GDC-6036 is administered QD according to a dosing regimen comprising one or more 21-day cycles; and inarliseb, wherein inarliseb is administered QD according to a dosing regimen comprising one or more 21-day cycles. In another embodiment, the combination therapy can be used to treat a KRas G12C A combination therapy for a lung cancer with a mutation, wherein the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate), wherein GDC-6036 is administered QD according to a dosing regimen comprising one or more 28-day cycles; and inarliseb, wherein inarliseb is administered QD according to a dosing regimen comprising one or more 28-day cycles. In a preferred embodiment, the lung cancer is NSCLC (e.g., metastatic NSCLC).
[0078] In another embodiment, the invention can be used to treat a KRas G12CA combination therapy for a mutated lung cancer, wherein the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate), wherein GDC-6036 is administered QD in an amount of about 50 mg to 500 mg according to a dosing regimen comprising one or more 21-day cycles; and inarliseb, wherein inarliseb is administered QD in an amount of about 3 mg, 6 mg, or 9 mg according to a dosing regimen comprising one or more 21-day cycles. In one such embodiment, inarliseb is administered in an amount of 6 mg. In another embodiment, inarliseb is administered in an amount of 9 mg. In another embodiment, inarliseb is administered in an amount of 3 mg. In one embodiment, lung cancer is NSCLC. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg.
[0079] In another embodiment, the invention can be used to treat a KRas G12C A combination therapy for a mutated lung cancer, wherein the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate), wherein GDC-6036 is administered QD in an amount of about 50 mg to 500 mg according to a dosing regimen comprising one or more 28-day cycles; and inarliseb, wherein inarliseb is administered QD in an amount of about 3 mg, 6 mg, or 9 mg according to a dosing regimen comprising one or more 28-day cycles. In one such embodiment, inarliseb is administered in an amount of 6 mg. In another embodiment, inarliseb is administered in an amount of 9 mg. In another embodiment, inarliseb is administered in an amount of 3 mg. In one embodiment, lung cancer is NSCLC. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg.
[0080] In yet another embodiment, the invention is a method for treating a KRas- G12C In a specific embodiment, the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate) and inaricep, wherein the combination therapy is used to treat a solid tumor comprising KRas as described herein. G12C In one such embodiment, the solid tumor is CRC, breast cancer, or pancreatic cancer. In one embodiment, GDC-6036 is administered at 200 or 400 mg and inaricep is administered at 6 or 9 mg.
[0081] In another embodiment, the invention can be used to treat a KRas-containing G12CA combination therapy for a mutated solid tumor, wherein the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate), wherein GDC-6036 is administered QD in an amount as described herein according to a dosing regimen comprising one or more 21-day cycles; and inarliseb, wherein inarliseb is administered QD in an amount of about 3 mg, 6 mg, or 9 mg according to a dosing regimen comprising one or more 21-day cycles. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg.
[0082] In another embodiment, the invention can be used to treat a KRas-containing G12C A combination therapy for a mutated solid tumor, wherein the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate), wherein GDC-6036 is administered QD in an amount as described herein according to a dosing regimen comprising one or more 28-day cycles; and inarliseb, wherein inarliseb is administered QD in an amount of about 3 mg, 6 mg, or 9 mg according to a dosing regimen comprising one or more 28-day cycles. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg.
[0083] In yet another embodiment, the invention is a method for treating a KRas- G12C In a specific embodiment, the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate) and inaricep, wherein the combination therapy is used to treat a tumor comprising KRas as described herein. G12C Mutated histologically indeterminate cancers.
[0084] In another embodiment, the invention can be used to treat a KRas G12C Combination therapy for mutated tissue-indeterminate cancers, wherein the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate), wherein GDC-6036 is administered QD in an amount as described herein according to a dosing regimen comprising one or more 21-day cycles; and inarliseb, wherein inarliseb is administered QD in an amount of about 3 mg, 6 mg, or 9 mg according to a dosing regimen comprising one or more 21-day cycles. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg.
[0085] In another embodiment, the invention can be used to treat a KRas G12CCombination therapy for a mutated tissue-indeterminate cancer, wherein the combination therapy comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate), wherein GDC-6036 is administered QD in an amount as described herein according to a dosing regimen comprising one or more 28-day cycles; and inarliseb, wherein inarliseb is administered QD in an amount of about 3 mg, 6 mg, or 9 mg according to a dosing regimen comprising one or more 28-day cycles. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg.
[0086] Treatment
[0087] In one aspect, a method for treating a patient with a KRas G12C A method for treating lung cancer in a patient with a mutated lung cancer, the method comprising administering to the patient an effective amount of a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof (eg, GDC-6036 adipate) and inaricep.
[0088] In one embodiment of the methods provided herein, the lung cancer is non-small cell lung cancer (NSCLC). In another embodiment of the methods provided herein, the lung cancer is adenocarcinoma, squamous cell lung cancer, or large cell lung cancer. In one such embodiment, the cancer is lung adenocarcinoma. In another such embodiment, the lung cancer is small cell lung cancer. In another embodiment, the lung cancer is small cell lung cancer. In yet another embodiment, the lung cancer is an adenoma, a carcinoid tumor, or an undifferentiated carcinoma. The lung cancer may be stage I or stage II lung cancer. In one embodiment, the lung cancer is stage III or stage IV lung cancer.
[0089] Also provided herein is a method for treating a patient with a KRas G12C A method (M1) for treating such cancer in patients with NSCLC with a mutation, wherein the method comprises administering to the patient an effective amount of a combination therapy as described herein, the combination therapy comprising (i) GDC-6036 or a pharmaceutically acceptable salt thereof according to a dosing regimen QD comprising one or more 21-day cycles; and (ii) inaricep according to a dosing regimen QD comprising one or more 21-day cycles. In one embodiment of the method provided herein, the method is used to treat adenocarcinoma. In one embodiment of the method provided herein, the method comprises 2 or more cycles. In one such embodiment, the method is used to treat first-line NSCLC.
[0090] Also provided herein is a method for treating a patient with a KRas G12CA method for treating such cancer in patients with NSCLC with a mutation (M2), wherein the method comprises administering to the patient an effective amount of a combination therapy as described herein, the combination therapy comprising (i) GDC-6036 or a pharmaceutically acceptable salt thereof according to a dosing regimen QD comprising one or more 28-day cycles; and (ii) inaricep according to a dosing regimen QD comprising one or more 28-day cycles. In one embodiment of the methods provided herein, the method is used to treat adenocarcinoma. In one embodiment of the methods provided herein, the method comprises 2 or more cycles. In one such embodiment, the method is used to treat first-line NSCLC.
[0091] Also provided herein is a method for treating a patient with a KRas G12C A method for treating such cancer in patients with NSCLC with a mutation (M3), wherein the method comprises administering to the patient an effective amount of a combination therapy comprising a dosing regimen as described herein, the dosing regimen comprising: (i) administering 50 mg to 500 mg of GDC-6036 or a pharmaceutically acceptable salt thereof QD according to a dosing regimen comprising one or more 21-day cycles; and (ii) administering about 3 mg, 6 mg, or 9 mg of inaricep QD according to a dosing regimen comprising one or more 21-day cycles. In one such embodiment, the dosing regimen includes a rest period in which one or both of GDC-6036 and / or inaricep are not administered. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inaricep is administered at 6 or 9 mg.
[0092] Also provided herein is a method for treating a patient with a KRas G12C A method for treating such cancer in patients with NSCLC with a mutation (M4), wherein the method comprises administering to the patient an effective amount of a combination therapy comprising a dosing regimen as described herein, the dosing regimen comprising: (i) administering 50 mg to 500 mg of GDC-6036 or a pharmaceutically acceptable salt thereof QD according to a dosing regimen comprising one or more 28-day cycles; and (ii) administering about 3 mg, 6 mg or 9 mg of inaricep QD according to a dosing regimen comprising one or more 28-day cycles. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inaricep is administered at 6 or 9 mg.
[0093] In embodiments M1 to M4, the method may further include (a) determining the absence or presence of a KRasG12C mutation in a sample taken from a patient with a suspected diagnosis of cancer; and (b) administering to the patient a combination therapy as described herein, the combination therapy comprising an effective amount of GDC-6036 or a pharmaceutically acceptable salt thereof and inarliside as described herein. In one such embodiment, the method further includes (c) not conducting an assessment for the presence of mutant PIK3CA prior to administering inarliside as described herein.
[0094] In another aspect, a method for treating a patient with a KRas G12C A method (M5) for treating a patient with a solid tumor with a mutation, the method comprising administering to the patient an effective amount of a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate) and inarliseb. In one such embodiment, the method comprises administering to the patient an effective amount of a combination therapy as described herein, the combination therapy comprising: (i) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen comprising one or more 21-day cycles; and (ii) inarliseb or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen comprising one or more 21-day cycles. In one such embodiment, the dosing regimen comprises a rest period, wherein one or both of GDC-6036 and / or inarliseb are not administered. In one such embodiment, the rest period is 7 days.
[0095] In another aspect, a method for treating a patient with a KRas G12C Method (M6) for treating such solid tumors in patients with mutated solid tumors, the method comprising administering to the patient an effective amount of a combination therapy as described herein, the combination therapy comprising: (i) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen including one or more 28-day cycles; and (ii) inarliside or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen including one or more 28-day cycles. In one embodiment of the method M5 or M6 provided herein, the method comprises 2 or more cycles. In one such embodiment of the method M5 or M6, GDC-6036 is administered in an amount of about 50 mg to 500 mg, and inarliside is administered in an amount of 3 mg, 6 mg or 9 mg. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliside is administered at 6 or 9 mg. In another embodiment, the patient is evaluated for the presence of a KRasG12C mutation, but before administering the combination therapy described herein, no assessment is performed for the presence of mutant PIK3CA. In one embodiment of the methods M5 or M6 described herein, the solid tumor is colorectal cancer (CRC). In one such embodiment, CRC is metastatic CRC (mCRC).
[0096] Further provided herein is a method (M7) for treating such cancer in a patient with an undefined type of cancer comprising a KRasG12C mutation, wherein the method comprises (i) determining the absence or presence of a KRasG12C mutation in a sample taken from a patient with a suspected diagnosis of cancer; and (ii) administering an effective amount of a combination therapy comprising: (a) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen including one or more 21-day cycles; and (b) inarliside or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen including one or more 21-day cycles. In one such embodiment, prior to administering inarliside as described herein, the patient sample is not evaluated for the presence of mutant PIK3CA. In one such embodiment of method M7, the dosing regimen includes a rest period in which one or both of GDC-6036 and / or inarliside are not administered. In one such embodiment, the rest period is 7 days.
[0097] Further provided herein is a method for treating such cancer in a patient with an undefined type of cancer comprising a KRasG12C mutation (M8), wherein the method comprises (i) determining the absence or presence of a KRasG12C mutation in a sample taken from a patient with a suspected diagnosis of cancer; and (ii) administering an effective amount of a combination therapy comprising: (a) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen comprising one or more 28-day cycles; and (b) inarliside or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen comprising one or more 28-day cycles. In one such embodiment, prior to administering inarliside as described herein, the patient sample is not evaluated for the presence of mutant PIK3CA.
[0098] In one embodiment of methods M7 and M8, the patient sample is further analyzed for the absence or presence of a PI3K mutation, such as those described herein.
[0099] In one embodiment of the methods described herein, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 5 mg to 600 mg, 5 mg to 500 mg, 5 mg to 400 mg, 5 mg to 300 mg, 5 mg to 250 mg, 5 mg to 200 mg, 5 mg to 150 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 25 mg to 600 mg, 25 mg to 500 mg, 25 mg to 400 mg, 25 mg to 300 mg. In another embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg or 500 mg. In another embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg or 800 mg. In another embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg or 400 mg. In one embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD as described herein in an amount of 100 mg. In one embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD as described herein in an amount of 200 mg. In one embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD as described herein in an amount of 400 mg. In another embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 to 300 mg. In another such embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 300 to 600 mg. In a preferred embodiment, GDC-6036 of the combination therapy described herein is administered in the form of an adipate salt. In such embodiments, the amount of GDC-6036 or a pharmaceutically acceptable salt thereof is administered relative to the amount of the free base form.
[0100] In one embodiment, inaricep is administered QD as described herein in an amount of 6 mg. In another embodiment, inaricep is administered QD as described herein in an amount of 9 mg. In another embodiment, inaricep is administered QD as described herein in an amount of 3 mg.
[0101] In one embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of 200 mg according to the methods described herein, and inaricep is administered in an amount of 6 mg according to the methods described herein. In one embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of 400 mg according to the methods described herein, and inaricep is administered in an amount of 6 mg according to the methods described herein.
[0102] In one embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of 200 mg according to the methods described herein, and inaricep is administered in an amount of 3 mg according to the methods described herein. In one embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of 200 mg according to the methods described herein, and inaricep is administered in an amount of 9 mg according to the methods described herein. In one embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of 400 mg according to the methods described herein, and inaricep is administered in an amount of 3 mg according to the methods described herein. In one embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of 400 mg according to the methods described herein, and inaricep is administered in an amount of 9 mg according to the methods described herein.
[0103] In some cases, the amount of inaricep administered can be adjusted from the initial administration of 6 mg to 9 mg. When 6 mg of inaricep as described herein is administered to a patient described herein and such administration is not tolerated, the amount of inaricep administered to the patient can be reduced to 3 mg. Similarly, when 9 mg of inaricep as described herein is administered to a patient described herein and such administration is not tolerated, the amount of inaricep administered to the patient can be reduced to 6 mg or 3 mg. As used herein, "tumor uncertainty" refers to a tumor specific for a KRas G12C Any solid tumor tested for the presence of mutations.
[0104] The methods provided herein can include administering the combination therapy described herein as part of a dosing regimen. In one such embodiment, the dosing regimen includes one or more cycles. In another embodiment, the dosing regimen includes at least 2 cycles. In another embodiment, the dosing regimen includes 2 to 3 cycles. In yet another embodiment, the dosing regimen includes at least 4, 6, 8, 10 or 12 cycles. In another aspect provided herein, the dosing regimen includes 2, 3, 4, 5, 6, 8, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 66 or 72 cycles. In yet another embodiment, the dosing regimen includes about 2-72, 2-66, 2-60, 2-54, 2-48, 2-42, 2-36, 2-30, 2-24, 2-18, 2-12 or 2-6 cycles. In one embodiment, the dosing regimen includes administering a combination therapy as described herein in any number of cycles until the expected relief (e.g., PFS, OS, ORR, and / or DOR) reaches the expected result (e.g., an increase in PFS, OS, ORR, and / or DOR compared to a control as described herein). In another embodiment, the dosing regimen includes administering a combination therapy as described herein in any number of cycles until toxicity occurs or the patient additionally experiences one or more adverse events (AEs) that prevent further administration. In such embodiments, the amount of the administered agent (e.g., GDC-6036 or a pharmaceutically acceptable salt thereof or inaricep) can be adjusted to reduce or eliminate AEs and allow cycles to be added to the dosing regimen. In yet another embodiment, the dosing regimen includes administering a combination therapy as described herein in any number of cycles until disease progression.
[0105] In some cases, the methods described herein comprise administering one or more additional therapies, wherein the additional therapies are one or more side effect limiting agents (e.g., agents intended to reduce the occurrence and / or severity of therapeutic side effects, such as antiemetics, corticosteroids (e.g., prednisone or equivalent, e.g., at a dose of 1 to 2 mg / kg / day), hormone replacement medications, etc.).
[0106] Patients as provided herein must be evaluated and have KRas as described herein G12C In one such embodiment, the patient has been previously treated with one or more prior therapies. G12CPatients with a confirmatory test result for a mutation must not have a known concomitant second oncogenic driver (e.g., for NSCLC: sensitizing EGFR mutation, ALK rearrangement, ROS1 rearrangement, BRAF V600E mutation, NTRK fusion, RET fusion; or for adenocarcinoma of the colon or rectum: BRAF V600E mutation, ERBB2 amplification). In one such embodiment, the patient has previously been treated with one or more prior therapies. In one embodiment, such a second oncogenic driver is determined using NGS (e.g., determined by Foundation Medicine, Inc. (FMI) NGS assay).
[0107] In one embodiment, a patient as provided herein must be evaluated and have a KRas G12C Confirmatory test results for mutations, and patients have not been evaluated for the presence of mutant PIK3CA with mutations at one or more of the following positions: 88, 106, 111, 118, 345, 420, 453, 542, 545, 546, 1043, 1047, and 1049 (e.g., H1047, E545, E542, Q546, N345, C420, M1043, G1049, E453, K111, G106, G118, and R88).
[0108] In one embodiment, the patient described herein has received KRas G12C Prior treatment with specific inhibitors.
[0109] In another embodiment, the patient described herein has not been treated with chemotherapy, immunotherapy, or biological therapy as an anti-cancer therapy within 3 weeks prior to administration of the combination therapy described herein, or has not been treated with endocrine therapy as an anti-cancer therapy within 2 weeks prior to administration of the combination therapy described herein, except for the following:
[0110] (a) Hormonal therapy using gonadotropin-releasing hormone (GnRH) agonists or antagonists for endocrine-sensitive cancers (e.g. prostate cancer, endometrial cancer, hormone receptor-positive breast cancer);
[0111] (b) kinase inhibitors approved by regulatory agencies may be used up to 2 weeks prior to administration of the combination therapy described herein, provided that any drug-related toxicity has resolved; or
[0112] (c) treatment with the investigational agent within 3 weeks or five half-lives prior to administration of the combination therapy described herein, whichever is shorter.
[0113] In another embodiment, the patient described herein has not received radiation therapy as a cancer therapy (except for palliative radiation to bone metastases and radiation to CNS metastases as described above) within 4 weeks prior to starting administration of the combination therapy described herein. In yet another embodiment, the patient described herein has not received palliative radiation to bone metastases within 2 weeks prior to administration of the combination therapy described herein.
[0114] In another embodiment, the patients described herein do not have a history of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonia, or evidence of active pneumonia on a chest computed tomography (CT) scan.
[0115] Further provided herein is the use of the combination therapy described herein comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep for treating lung cancer as described herein (UL1). In one embodiment, the use of the combination therapy described herein comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep for treating NSCLC as described herein (UL2).
[0116] Further provided herein is a combination therapy for treating lung cancer as described herein (UL3), wherein the combination therapy comprises: (i) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen comprising one or more 21-day cycles; and (ii) inarliseb administered QD according to a dosing regimen comprising one or more 21-day cycles. In one such embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 50 to 500 mg. In another such embodiment, inarliseb is administered in an amount of about 6 mg. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg. In another embodiment, the patient is evaluated for the presence of a KRasG12C mutation, but no evaluation for the presence of a mutant PIK3CA is performed prior to administering the combination therapy described herein.
[0117] Further provided herein is a combination therapy for treating lung cancer as described herein (UL4), wherein the combination therapy comprises: (i) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen comprising one or more 28-day cycles; and (ii) inarliseb administered QD according to a dosing regimen comprising one or more 28-day cycles. In one such embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 50 to 500 mg. In another such embodiment, inarliseb is administered in an amount of about 6 mg. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg. In another embodiment, the patient is assessed for the presence of a KRasG12C mutation, but no assessment for the presence of a mutant PIK3CA is performed prior to administering the combination therapy described herein.
[0118] Further provided herein is the use of the combination therapy described herein for treating lung cancer as described herein (UL5), wherein the combination therapy comprises: (i) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD in an amount of about 50 to 500 mg according to a dosing regimen comprising one or more 21-day cycles; and (ii) inarliseb administered QD in an amount of 3 mg, 6 mg or 9 mg according to a dosing regimen comprising one or more 21-day cycles. In one such embodiment, the dosing regimen comprises 2 or more cycles as described herein. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg. In another embodiment, the patient is evaluated for the presence of a KRasG12C mutation, but no evaluation for the presence of a mutant PIK3CA is performed prior to administering the combination therapy described herein.
[0119] Further provided herein is the use of the combination therapy described herein for treating lung cancer as described herein (UL6), wherein the combination therapy comprises: (i) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD in an amount of about 50 to 500 mg according to a dosing regimen comprising one or more 28-day cycles; and (ii) inarliseb administered QD in an amount of 3 mg, 6 mg or 9 mg according to a dosing regimen comprising one or more 28-day cycles. In one such embodiment, the dosing regimen comprises 2 or more cycles as described herein. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg. In another embodiment, the patient is evaluated for the presence of a KRasG12C mutation, but an evaluation for the presence of a mutant PIK3CA is not performed prior to administering the combination therapy described herein.
[0120] Further provided herein is the use of a combination therapy as described herein comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep for the manufacture of a medicament (UL7) for the treatment of lung cancer as described herein.
[0121] Further provided herein is the use of the combination therapy described herein for the manufacture of a medicament (UL8), which is used to treat lung cancer as described herein, wherein the combination therapy comprises: (i) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen including one or more 21-day cycles; and (ii) inarliseb administered QD according to a dosing regimen including one or more 21-day cycles. In one such embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 50 to 500 mg. In another such embodiment, inarliseb is administered in an amount of about 3 mg, 6 mg or 9 mg. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg. In another embodiment, the patient is evaluated for the presence of a KRasG12C mutation, but no evaluation for the presence of mutant PIK3CA is performed prior to administering the combination therapy described herein.
[0122] Further provided herein is the use of the combination therapy described herein for the manufacture of a medicament (UL9), which is used to treat lung cancer as described herein, wherein the combination therapy comprises: (i) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD according to a dosing regimen including one or more 28-day cycles; and (ii) inarliseb administered QD according to a dosing regimen including one or more 28-day cycles. In one such embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 50 to 500 mg. In another such embodiment, inarliseb is administered in an amount of about 3 mg, 6 mg or 9 mg. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg. In another embodiment, the patient is evaluated for the presence of a KRasG12C mutation, but no evaluation for the presence of a mutant PIK3CA is performed prior to administering the combination therapy described herein.
[0123] In such embodiments of the uses described herein (UL1-UL8), the patient described herein is diagnosed with a disease caused by KRas G12C Mutation-mediated NSCLC.
[0124] Further provided herein is the use of a combination therapy as described herein comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep for treating a solid tumor as described herein (UC1).
[0125] Further provided herein is the use of the combination therapy described herein for treating a solid tumor as described herein (UC2), wherein the combination therapy comprises: (i) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD in an amount of about 50 to 500 mg according to a dosing regimen comprising one or more 21-day cycles; and (ii) inarliseb administered QD in an amount of 3 mg, 6 mg or 9 mg according to a dosing regimen comprising one or more 21-day cycles. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg. In another embodiment, the patient is evaluated for the presence of a KRasG12C mutation, but an evaluation for the presence of a mutant PIK3CA is not performed prior to administering the combination therapy described herein.
[0126] Further provided herein is the use of the combination therapy described herein for treating a solid tumor as described herein (UC3), wherein the combination therapy comprises: (i) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD in an amount of about 50 to 500 mg according to a dosing regimen comprising one or more 28-day cycles; and (ii) inarliseb administered QD in an amount of 3 mg, 6 mg or 9 mg according to a dosing regimen comprising one or more 28-day cycles. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg. In another embodiment, the patient is assessed for the presence of a KRasG12C mutation, but an assessment for the presence of a mutant PIK3CA is not performed prior to administering the combination therapy described herein.
[0127] In such embodiments of uses UC1-UC3 described herein, the patient described herein is diagnosed with a disease caused by KRas G12C Mutation-mediated CRC.
[0128] Further provided herein is the use of the combination therapy described herein for treating an undefined type of cancer comprising a KRasG12C mutation as described herein (UA1), wherein a sample taken from a patient with a suspected diagnosis of cancer is tested for the absence or presence of a KRasG12C mutation; and in the case where the patient sample comprises a KRasG12C mutation, an effective amount of the combination therapy is administered: (a) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD in an amount of about 50 to 500 mg QD according to a dosing regimen comprising one or more 21-day cycles; and (b) inarliseb administered QD in an amount of 3 mg, 6 mg or 9 mg according to a dosing regimen comprising one or more 21-day cycles. In such embodiments, GDC-6036 and inarliseb can be administered as described herein and in accordance with the uses and methods provided herein. In one embodiment, GDC-6036 is administered at 200 or 400 mg, and inarliseb is administered at 6 or 9 mg. In another embodiment, the patient is assessed for the presence of the KRasG12C mutation, but is not assessed for the presence of mutant PIK3CA prior to administration of the combination therapy described herein.
[0129] Further provided herein is the use of the combination therapy described herein for treating an undefined type of cancer comprising a KRasG12C mutation as described herein (UA2), wherein a sample taken from a patient with a suspected diagnosis of cancer is tested for the absence or presence of a KRasG12C mutation; and in the case where the patient sample comprises a KRasG12C mutation, an effective amount of the combination therapy is administered: (a) GDC-6036 or a pharmaceutically acceptable salt thereof administered QD in an amount of about 50 to 500 mg QD according to a dosing regimen comprising one or more 28-day cycles; and (b) inarlised administered QD in an amount of 3 mg, 6 mg or 9 mg according to a dosing regimen comprising one or more 28-day cycles. In such embodiments, GDC-6036 and inarlised can be administered as described herein and in accordance with the uses and methods provided herein. In one embodiment, before administering the combination therapy described herein, the patient sample is not evaluated for the presence of mutant PIK3CA.
[0130] In one embodiment of uses UA1 and UA2, the patient sample is further analyzed for the absence or presence of a PI3K mutation such as those described herein.
[0131] The development of combination therapy presents challenges, including, for example, the selection of agents for combination therapy that can improve efficacy while maintaining acceptable toxicity. A particular challenge is the need to distinguish the incremental toxicity of the combination. In one embodiment of the methods described herein, the combination therapy described herein (e.g., GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep) is administered with a dosing regimen comprising a staggered dosing schedule. In one such embodiment, compared to a control (e.g., SOC therapy, treatment with one of the agents described herein (e.g., GDC-6036 or inaricep) alone), the number of adverse events (AEs) in patients is reduced or their grade is reduced.
[0132] As is generally known, when an adverse event occurs, there are four options: (1) continue the original treatment with optional concomitant therapy; (2) adjust the dose of one or more agents in the dosing regimen; (3) suspend the administration of one or more agents in the dosing regimen; or (4) terminate the administration of one or more agents in the dosing regimen. In one embodiment, the amount of GDC-6036 administered is not changed. In another embodiment, the amount of inaricep administered is not changed. In one embodiment, when the administration of an agent described herein (e.g., GDC-6036 or a pharmaceutically acceptable salt thereof or inaricep) is interrupted, the next administration of the corresponding agent occurs on the same day that GDC-6036 is resumed. In one embodiment, GDC-6036 or a pharmaceutically acceptable salt thereof is not administered with food (i.e., the patient should not eat for at least 2 hours before administration and at least 1 hour after administration).
[0133] In one embodiment, the patient described herein experienced gastrointestinal toxicity with an AE grade of less than or equal to 2. In one such embodiment, the gastrointestinal toxicity is diarrhea, nausea, or vomiting. In another embodiment, the patient described herein experienced phototoxicity. In such embodiments, the patient should wear sunscreen and protective clothing when outdoors.
[0134] Patients described herein may also be administered concomitant therapy, including: (a) anti-epileptic medications or warfarin; (b) oral contraceptives or other permitted maintenance therapy; (c) antiemetics and antidiarrheals, provided that such medications should not be administered prophylactically prior to initiation of study drug treatment; (d) analgesics administered in accordance with standard clinical practice; (e) bisphosphonates and denosumab therapy for bone metastases or osteopenia / osteoporosis; or (f) multivitamins, calcium, and vitamins C, D, and E supplements.
[0135] Patients described herein should not be taking concomitant therapies that include: (1) strong / moderate CYP3A4 inhibitors (e.g., atazanavir, ritonavir, indinavir, nelfinavir, saquinavir, clarithromycin, telithromycin, erythromycin, troleandomycin, fluconazole, itraconazole, ketoconazole, voriconazole, posaconazole, aprepitant, conivaptan, fluvoxamine, diltiazem, nefazodone, mibefradil, verapamil, and grapefruit juice or grapefruit supplements) or (2) strong / moderate CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, oxcarbazepine, phenobarbital, efavirenz, nevirapine, etravirine, modafinil, hyperforin (St. John's wort), and cyproterone acetate).
[0136] In another embodiment, the patients described herein are not administered medications that reduce gastric acid production, such as proton pump inhibitors or H2 receptor antagonists.
[0137] In another embodiment, the patient described herein is not administered any of the following therapies:
[0138] (a) any other investigational therapy (excluding GDC-6036 or inaricep) for 3 weeks or five half-lives (whichever is shorter) prior to administration of a combination therapy described herein or during such treatment;
[0139] (b) Concomitant therapy intended to treat cancer, whether FDA-approved or experimental, including chemotherapy, radiation therapy, immunotherapy, biological therapy, traditional Chinese medicine, or hormonal therapy, except:
[0140] (i) Hormonal therapy using gonadotropin-releasing hormone (GnRH) agonists or antagonists for endocrine-sensitive cancers (e.g. prostate cancer, endometrial cancer, hormone receptor-positive breast cancer);
[0141] (ii) hormone replacement therapy or oral contraceptives;
[0142] (c) Radiation therapy for clear progressive disease, except for new brain metastases in the setting of a systemic response: Patients who have demonstrated control of their systemic disease (defined as having achieved clinical benefit [i.e., PR, CR, or SD lasting ≥3 months]) but have developed brain metastases that are amenable to radiation therapy will be allowed to continue therapy with GDC-6036 during the study until they experience systemic progression of their disease and / or further progression in the brain (based on investigator assessment).
[0143] (d) quinidine or other antiarrhythmic agents; or
[0144] (e) starting or increasing the dose of hematopoietic colony-stimulating factors (CSF; e.g., granulocyte CSF; filgrastim, granulocyte / macrophage CSF; sargramostim, pegfilgrastim, erythropoietin, darbepoietin, and thrombopoietin) from 7 days before day 1 of cycle 1;
[0145] In one embodiment of such methods, the patient is diagnosed with a cancer as described herein. In another embodiment of such methods, the sample is a tumor sample taken from the subject. In one such embodiment, the sample is collected prior to administering any therapy described herein. In another such embodiment, the sample is collected prior to administering at least one agent described herein. In some embodiments, tumor samples may be collected at specific time intervals during treatment with a combination therapy described herein to assess treatment.
[0146] Whether a tumor or cancer contains KRas can be determined by evaluating the nucleotide sequence encoding the K-Ras protein, by evaluating the amino acid sequence of the K-Ras protein, or by evaluating the characteristics of a putative K-Ras mutant protein. G12C Mutation. The sequence of wild-type human K-Ras (e.g., accession number NP203524) is known in the art. In one such embodiment, KRas from samples of patients described herein are assessed using, for example, immunohistochemistry (IHC) or NGS sequencing. G12C mutation.
[0147] In one embodiment of the methods provided herein, after treatment with the combination therapy according to the methods provided herein, the patient is diagnosed with a CR. In one embodiment of the methods provided herein, after treatment with the combination therapy according to the methods provided herein, the patient is diagnosed with a PR. In one embodiment of the methods provided herein, after treatment with the combination therapy according to the methods provided herein, the patient is diagnosed with a stable disease (SD).
[0148] Also provided herein are methods for inhibiting tumor growth or producing tumor regression in patients described herein, which are achieved by administering the combination therapy described herein. In one embodiment provided herein, a method for inhibiting tumor growth in patients with cancer described herein, the method is performed by administering a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inarlised in one or more cycles (e.g., 21 or 28 day cycles) as described herein. In one embodiment provided herein, a method for inhibiting tumor growth in patients with NSCLC or CRC as described herein, the method is performed by administering a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inarlised in one or more cycles (e.g., 21 or 28 day cycles) as described herein.
[0149] In one embodiment provided herein, a method of producing or improving tumor regression in a patient with a cancer as described herein, the method being performed by administering a combination therapy comprising administering GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep in one or more cycles (e.g., 21 or 28 day cycles) as described herein. In one embodiment provided herein, a method of producing or improving tumor regression in a patient with NSCLC or CRC as described herein, the method being performed by administering a combination therapy comprising administering GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep in one or more cycles (e.g., 21 or 28 day cycles) as described herein.
[0150] Reagent test kit
[0151] The combination therapy described herein can be provided in the form of a kit comprising one or more of the agents described herein for administration. In one embodiment, the kit comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate) for administration in combination with inarise. In another embodiment, the kit comprises GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate) packaged with inarise, wherein the kit comprises separate formulated doses of each agent.
[0152] Also provided herein is an article or kit comprising GDC-6036 or a pharmaceutically acceptable salt thereof (e.g., GDC-6036 adipate) and inarlised. In some cases, the article further comprises one or more package inserts comprising instructions for using the agents described herein to treat solid tumors (e.g., lung cancer or CRC) or delay their progression. In one such embodiment, the cancer is NSCLC.
[0153] In some cases, inarisip and GDC-6036 or its pharmaceutical salt (e.g., GDC-6036 adipate) are in the same container or separate containers. Suitable containers include, for example, bottles, vials, bags, and syringes. The container can be formed of a variety of materials, such as glass, plastics (such as polyvinyl chloride or polyolefins) or metal alloys (such as stainless steel or Hastelloy). In some cases, the container holds the preparation, and the label on the container or associated with the container can indicate instructions for use. The product or test kit can also include other materials desired from a commercial and user perspective, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. In some cases, the product further includes one or more other agents (e.g., additional chemotherapeutic agents and antitumor agents). Suitable containers for one or more reagents include, for example, bottles, vials, bags, and syringes.
[0154] Any article of manufacture or kit described herein may include instructions for administering GDC-6036 or a pharmaceutically acceptable salt thereof (eg, GDC-6036 adipate) and / or inaricep to a patient according to any method described herein.
[0155] Biomarkers
[0156] In one embodiment, prior to administering a combination therapy as described herein, a patient as described herein must be evaluated for and have a confirmed KRasG12C mutation. In one such embodiment, an assessment for the presence of mutant PIK3CA is not performed prior to administering a combination therapy as described herein.
[0157] In one embodiment, the effect of GDC-6036 or a pharmaceutically acceptable salt thereof on KRas is measured in a patient. G12C In one such embodiment, the samples are used to measure and test the KRas G12C In another embodiment, ctDNA biomarkers (e.g., KRas G12C ) for evaluation.
[0158] In one embodiment, modulation of KRAS / MAPK target genes (e.g., DUSP6, SPRY4), pathway components (e.g., pERK, pS6), and relevant biomarkers (e.g., Ki67) is performed by analyzing paired pre-treatment and on-treatment fresh tumor biopsies.
[0159] Inarliside is a selective inhibitor of the class I PI3Kα isoform (p110α). Without being bound by any particular theory, it may inhibit PIP 2 Phosphorylation to PIP 3 , inaricep reduces the activation of downstream pathway effectors including AKT, PRAS40, and S6RP, which may serve as PD biomarkers for treatment with GDC-6036 and inaricep.
[0160] Example
[0161] Some exemplary embodiments of the present invention are provided below.
[0162] Example 1. A combination therapy comprising:
[0163] (a) GDC-6036 as described herein or a pharmaceutically acceptable salt thereof; and
[0164] (b) Inaricep or a pharmaceutically acceptable salt thereof as described herein.
[0165] Embodiment 2. The combination therapy according to embodiment 1, wherein GDC-6036 is its adipate salt.
[0166] Embodiment 3. The combination therapy according to Embodiment 1 or 2, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more cycles.
[0167] Embodiment 4. The combination therapy according to embodiment 3, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD on day 1 to day 21 of a dosing regimen comprising one or more 21-day cycles, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is orally administered in the form of a tablet or capsule.
[0168] Embodiment 5. The combination therapy according to Embodiment 3, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more 28-day cycles, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered orally in the form of a tablet or capsule.
[0169] Embodiment 6. The combination therapy according to any one of embodiments 1 to 5, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 50 mg to 500 mg.
[0170] Embodiment 7. The combination therapy according to any one of embodiments 1 to 6, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg or 800 mg.
[0171] Embodiment 8. The combination therapy according to any one of embodiments 1 to 6, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg or 400 mg.
[0172] Embodiment 9. The combination therapy according to any one of embodiments 1 to 6, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 200 mg.
[0173] Embodiment 10. The combination therapy according to any one of embodiments 1 to 6, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 400 mg.
[0174] Embodiment 11. The combination therapy according to any one of embodiments 1 to 10, wherein inaricep or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more cycles.
[0175] Embodiment 12. The combination therapy according to embodiment 11, wherein inaricep or a pharmaceutically acceptable salt thereof is administered QD on day 1 to day 21 of a dosing regimen comprising one or more 21-day cycles.
[0176] Embodiment 13. The combination therapy according to any one of Embodiments 1 to 12, wherein inaricep or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more 28-day cycles.
[0177] Embodiment 14. The combination therapy according to any one of embodiments 1 to 13, wherein the dosing regimen comprises a rest period, wherein one or both of GDC-6036 and inaricep are not administered.
[0178] Embodiment 15. The combination therapy according to any one of embodiments 1 to 14, wherein inaricep is administered in an amount of about 3 mg, 6 mg or 9 mg.
[0179] Embodiment 16. The combination therapy according to any one of embodiments 1 to 15, wherein inaricep is administered in an amount of 6 mg.
[0180] Embodiment 17. The combination therapy according to any one of embodiments 1 to 15, wherein inaricep is administered in an amount of 9 mg.
[0181] Embodiment 18. A combination therapy according to any one of embodiments 1 to 17 for the treatment of a disease comprising KRas G12C Mutated lung cancer.
[0182] Embodiment 19. The combination therapy according to embodiment 18, wherein the lung cancer is non-small cell lung cancer (NSCLC).
[0183] Embodiment 20. A combination therapy according to any one of embodiments 1 to 17 for the treatment of a disease comprising KRas G12C mutations in colorectal cancer (CRC).
[0184] Embodiment 21. The combination therapy according to any one of embodiments 1 to 20, wherein the patient is assessed for the presence of the KRasG12C mutation prior to administration.
[0185] Embodiment 22. The combination therapy according to any one of embodiments 1 to 21, wherein no assessment for the presence of mutant PIK3CA is performed prior to administration.
[0186] Example 23. A method for treating a patient suffering from KRas G12C A method for treating lung cancer in a patient with lung cancer mediated by a mutation thereof, the method comprising administering an effective amount of a combination therapy comprising:
[0187] (a) GDC-6036 or a pharmaceutically acceptable salt thereof as described herein, administered QD according to a dosing regimen comprising one or more cycles; and
[0188] (b) Inaricep or a pharmaceutically acceptable salt thereof as described herein, administered QD according to a dosing regimen comprising one or more cycles.
[0189] Embodiment 24. The method according to embodiment 23, wherein the lung cancer is NSCLC.
[0190] Embodiment 25. The method of embodiment 23 or 24, wherein the lung cancer is adenocarcinoma, squamous cell lung cancer, or large cell lung cancer.
[0191] Example 26. A method of treating a patient having a solid tumor comprising a KRasG12C mutation, the method comprising administering an effective amount of a combination therapy comprising:
[0192] (a) GDC-6036 or a pharmaceutically acceptable salt thereof as described herein, administered QD according to a dosing regimen comprising one or more cycles; and
[0193] (b) Inaricep or a pharmaceutically acceptable salt thereof as described herein, administered QD according to a dosing regimen comprising one or more cycles.
[0194] Embodiment 27. The method according to embodiment 26, wherein the solid tumor is colorectal cancer (CRC).
[0195] Embodiment 28. The method according to any one of embodiments 23 to 27, further comprising:
[0196] (a) determining the absence or presence of a KRasG12C mutation in a sample taken from a patient with a suspected diagnosis of cancer; and
[0197] (b) administering to the patient a combination therapy as described herein, said combination therapy comprising effective amounts of GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep.
[0198] Example 29. A method of treating a patient having a histologically indeterminate cancer comprising a KRasG12C mutation, the method comprising administering an effective amount of a combination therapy comprising:
[0199] (i) determining the absence or presence of a KRasG12C mutation in a sample taken from a patient with a suspected diagnosis of cancer; and
[0200] (ii) where the patient sample comprises the KRasG12C mutation, administering an effective amount of a combination therapy comprising:
[0201] (a) as described herein, administered QD according to a dosing regimen comprising one or more cycles
[0202] GDC-6036 or a pharmaceutically acceptable salt thereof; and
[0203] (b) Inaricep or a pharmaceutically acceptable salt thereof as described herein, administered QD according to a dosing regimen comprising one or more cycles.
[0204] Embodiment 30. The method of any one of embodiments 23 to 29, wherein the dosing regimen comprises one or more 21 day cycles.
[0205] Embodiment 31. The method of embodiment 30, wherein the dosing regimen comprises a rest period, wherein one or both of GDC-6036 and inaricep are not administered.
[0206] Embodiment 32. The method of any one of embodiments 23 to 29, wherein the dosing regimen comprises one or more 28-day cycles.
[0207] Embodiment 33. The combination therapy according to any one of embodiments 23 to 32, wherein GDC-6036 is its adipate salt.
[0208] Embodiment 34. The method according to any one of embodiments 23 to 33, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is orally administered in the form of a tablet or capsule.
[0209] Embodiment 35. The method of any one of embodiments 23 to 34, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 50 mg to 500 mg.
[0210] Embodiment 36. The method of any one of embodiments 23 to 35, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg or 800 mg.
[0211] Embodiment 37. The method of any one of embodiments 23 to 36, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg or 400 mg.
[0212] Embodiment 38. The method according to any one of embodiments 23 to 37, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 200 mg.
[0213] Embodiment 39. The method according to any one of embodiments 23 to 37, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 400 mg.
[0214] Embodiment 40. The method of any one of embodiments 23 to 39, wherein inaricep is administered in an amount of about 3 mg, 6 mg or 9 mg.
[0215] Embodiment 41. The method of any one of embodiments 23 to 40, wherein inaricep is administered in an amount of 6 mg.
[0216] Embodiment 42. The method of any one of embodiments 23 to 40, wherein inaricep is administered in an amount of 9 mg.
[0217] Embodiment 43. The method of any one of embodiments 23 to 42, wherein the patient is not assessed for the presence of mutant PIK3CA prior to administration.
[0218] Example 44. Use of a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep or a pharmaceutically acceptable salt thereof for treating lung cancer, CRC or pancreatic cancer as described herein.
[0219] Embodiment 45. The use according to embodiment 44, wherein the cancer is lung cancer or CRC, and further comprises a dosing regimen comprising: (i) administering GDC-6036 or a pharmaceutically acceptable salt thereof QD according to a dosing regimen comprising one or more cycles; and (ii) administering inarice QD according to the dosing regimen comprising one or more cycles.
[0220] Example 46. Use of a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of lung cancer, CRC or pancreatic cancer.
[0221] Embodiment 47. The use according to Embodiment 46, wherein the cancer is lung cancer or CRC, and further comprises a dosing regimen comprising: (i) administering GDC-6036 or a pharmaceutically acceptable salt thereof QD according to a dosing regimen comprising one or more cycles; and (ii) administering inarice QD according to the dosing regimen comprising one or more cycles.
[0222] Embodiment 48. The use according to embodiment 46, wherein the cancer is CRC, and further comprising a dosing regimen comprising: (i) administering GDC-6036 or a pharmaceutically acceptable salt thereof QD according to a dosing regimen comprising one or more 21-day cycles; and (ii) administering inaricep according to a dosing regimen comprising one or more 21-day cycles.
[0223] Embodiment 49. The use according to any one of embodiments 44 to 48, wherein the dosing regimen comprises one or more 21-day cycles.
[0224] Embodiment 50. The use according to any one of embodiments 44 to 48, wherein the dosing regimen comprises one or more 28-day cycles.
[0225] The following examples are offered by way of illustration only and not limitation.
[0226] Examples
[0227] Example 1: Combination of GDC-6036 and Inaricep
[0228] The Kirsten rat sarcoma viral oncogene homolog (KRAS) gene encodes a GTPase that plays a central role in mediating cell growth and survival signaling. Mutations in KRAS that result in glycine 12 (G12), glycine 13 (G13), and glutamine 61 (Q61) amino acid substitutions are common in tumors and are associated with tumorigenesis and maintenance of aggressive tumor growth (Der et al., Nature 1983; 304(5926):507-13; Parada et al., Nature 1982; 297(5866):474-8; Santos et al., Nature 1982; 298(5872):343-7; Taparowsky et al., Nature 1982; 300(5894):762-5; Capon et al., Nature 1983; 304(5926):507-13). KRAS G12C Mutations are prevalent in non-small cell lung cancer (NSCLC), colorectal cancer, and other tumor types (Prior et al., Cancer Res 2012; 72(10):2457-67; Vogelestein et al., Science 2013; 339(6127):1546-58).
[0229] GDC-6036 selectively targets KRAS G12C , which leads to KRAS G12C GDC-6036 does not target other mutations in KRAS, wild-type KRAS, or other members of the RAS family. G12C Positive cells or tumors weaken KRAS pathway signaling, inhibit cell / tumor cell growth and induce cell apoptosis.
[0230] GDC-6036 (50 mg / kg, PO, QD) alone or in combination with GDC-0077 (25 mg / kg, PO, QD) was evaluated for in vivo antitumor efficacy in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) xenograft tumor models carrying KRas G12C mutations. Single agent GDC-6036 treatment resulted in near tumor stasis (93% tumor growth inhibition [TGI]), while treatment with GDC-0077 resulted in tumor growth inhibition (74% TGI). Improved antitumor efficacy (113% TGI) was observed when GDC-6036 was administered in combination with inaricep.
[0231] Mice. Female nude mice aged 9 to 10 weeks were obtained from Charles River Laboratory (Hollister, CA) with an average weight of 24.5 g. Mice were housed in standard rodent microisolator cages at Genentech and acclimated to the study conditions for at least 3 days before tumor cell implantation. Only animals that appeared healthy and had no obvious abnormalities were used for the study.
[0232] Study. Human non-small cell lung cancer NCI-H2122 cells were obtained from the American Type Culture Collection (Rockville, MD) and have a G12C oncogenic mutation in K-RAS. Cells were cultured in vitro, harvested during the logarithmic growth phase, and resuspended in Hank's balanced salt solution containing Matrigel (BD Biosciences; San Jose, CA) at a 1:1 ratio. The cells were then implanted subcutaneously into the right flank of 160 nude mice. Each mouse was injected with 10x10 6 Tumors were monitored until they reached a mean tumor volume of 150 to 290 mm3. Mice were divided into 10 groups based on tumor volume, with n=10 mice per group. At the start of dosing, the mean tumor volume for all groups was 213 mm 3 .
[0233] Mice were administered vehicle (150 μL 0.5% MC and 100 μL 0.5% MCT), 50 mg / kg GDC-6036 (expressed as free base equivalents) or 25 mg / kg GDC-0077 (expressed as free base equivalents) or a combination of GDC-6036 and inaricep. All treatments were administered orally (PO) once a day (QD) by gavage for 21 days. The study design is summarized in Table 1.
[0234] Table 1:
[0235]
[0236] Tumor and body weight measurements. Tumor volume was measured in two dimensions (length and width) using Ultra Cal-IV calipers (model 54-10-111; Fred V. Fowler Co.; Newton, MA) and analyzed using Excel version 14.2.5 (Microsoft Corporation; Redmond WA). Tumor volume was calculated using the following formula:
[0237] Tumor size (mm 3 ) = (longer measurement x shorter measurement 2 )x 0.5
[0238] Antitumor responses were noted, with partial remission (PR) defined as a >50% reduction in tumor volume from the initial tumor volume, and complete remission (CR) defined as a 100% reduction in tumor volume. Animal body weights were measured using an Adventura Pro AV812 balance (Ohaus Corporation; Pine Brook, NJ). Percent weight change was calculated using the following formula:
[0239] Weight change (%) = [(current weight / initial weight) – 1) x 100]
[0240] Tumor growth analysis. The generalized additive mixed model (GAMM) was used to analyze the changes in the converted tumor volume over time because the method solved both repeated measurements from the same individual and moderate withdrawal before the end. Since tumors usually grow exponentially, natural logarithmic transformation was performed on tumor volume before analysis. The changes in tumor volume over time in each group were described by fitting (i.e., regression splines with automatically generated 3-spline bases) using custom functions in R version 3.4.2 (2017-09-28) (R Development Core Team 2008; R Foundation for Statistical Computing; Vienna, Austria), which integrates software from open source packages, including Ime4, mgcv, gamm4, multcomp, settings, plyr, and several packages from tidyverse, such as magrittr, dplyr, tidyr, and ggplot2.
[0241] Body weight analysis. Generalized additive mixed models (GAMM) were also used to analyze the change in raw body weight (i.e., grams) over time. After data fitting, the raw body weight data for each time point from all individual animals and all group fitting results were standardized and re-plotted separately in two different ways: 1) standardized to initial body weight and reported as a percentage to obtain % body weight change; and 2) standardized to the maximum body weight to date and reported as a percentage to obtain % weight loss.
[0242] Results. Efficacy and body weight of NCI-H2122 xenografts. Antitumor efficacy was evaluated in nude mice bearing human NCI-H2122 NSCLC xenografts after treatment with GDC-6036 alone (50 mg / kg, PO, QD), single agent GDC-0077 (25 mg / kg, PO, QD), or a dual combination of GDC-6036 and GDC-0077. Single agent treatment resulted in tumor growth inhibition (TGI) relative to vehicle control, with GDC-6036 resulting in 93% TGI and GDC-0077 resulting in 74% TGI ( Figure 1 Improved antitumor activity was observed with the combination of GDC-6036 and inaricep, resulting in 113% TGI and 2 / 10 PR ( Figure 1 All treatments were well tolerated as determined by percent body weight change ( Figure 2 and Table 2 ).
[0243] Table 2: Antitumor activity of GDC-6036 alone and in combination with GDC-0077 in human NCI-H2122 NSCLC xenograft tumors
[0244]
[0245] The combination of GDC-6036 and inarilisab is being further tested in various other NSCLC cell lines carrying KRasG12C mutations, including H23 P, KYSE410, H1792, H2030, HCC4017, HCC4019, and HOP62. Synergistic effects were observed at concentrations as low as 40 nM in some cell lines ( 3A to 3H ).
[0246] The combination of GDC-6036 and inarilicept was further tested in various CRC cell lines carrying KRasG12C mutations. Adding GDC-0077 to GDC-6036 further inhibited cell proliferation, even in the most resistant cell line (SW1436). FIG. 5A to FIG. 5CA synergistic effect of the combination of GDC-6036 and GDC-0077 was observed in the CR5048 patient-derived xenograft model ( Figure 4 and Table 3).
[0247] Table 3
[0248]
[0249] Combination antitumor efficacy studies performed in various human NSCLC and CRC xenograft tumor models and cell lines carrying the KRas G12C mutation demonstrated that the KRAS-G12C inhibitor GDC-6036 inhibited tumor growth as a single agent. These data suggest that the combination of GDC-6036 with GDC-0077 resulted in improved antitumor activity relative to the observation of single agents causing partial tumor regression in human NSCLC and CRC xenograft tumor models.
[0250] Example 2: KRAS is the most commonly mutated oncogene in up to 25% of cancers and is associated with resistance to selected standard of care therapies and an overall poor prognosis. Although selective inhibitors have been developed as anticancer therapies to target other nodes in the RAS / MAPK pathway, the KRAS oncoprotein was considered undruggable until the recent discovery of the switch II pocket (Ostrem, et al., Nature 2013; 503: 548-51). With this discovery, it is intended to target KRAS and specifically KRAS G12C Covalent small-molecule inhibitors of the mutation are being evaluated in early clinical development.
[0251] Other KRAS G12C AMG 510 (sotoracib) is a novel inhibitor of KRAS G12CA small molecule that irreversibly inhibits it by locking it in its inactive GDP-bound state. AMG 510 is currently being studied in ongoing clinical studies. Patients in those studies received a median of 3 (range, 0 to 11) lines of prior anticancer therapy for metastatic disease before entering the study. Overall, 56.6% of patients reported treatment-related adverse events; 11.6% of patients experienced treatment-related grade 3 or 4 events, and 1.6% of patients experienced treatment-related serious adverse events. Grade 3 events that occurred in more than one patient included elevated ALT, diarrhea, anemia, elevated AST, and elevated alkaline phosphatase. One patient experienced a grade 4 treatment-related elevation of ALT, and one patient discontinued AMG510 due to grade 3 treatment-related elevations of ALT and AST. Despite reported antitumor activity, there are adverse events associated with AMG 510. In 32.2% of NSCLC patients, patients had a confirmed objective response, and the median duration of response for patients was 10.9 months (range, 1.1+ to 13.6). The median PFS for patients with NSCLC was reported to be 6.3 months (range, 0.0+ to 14.9+) (Hong et al., New Eng J Med 2020;383:1207-17).
[0252] MRTX849 is a mutation-selective small molecule targeting KRAS G12C Inhibitors are being studied in a phase 2 trial with KRAS G12C The study was evaluated in a clinical study of patients with advanced solid tumors harboring mutations. Data from a total of 17 patients (including 10 NSCLC patients and 4 CRC patients) were recently reported, of which 12 patients underwent at least one on-treatment tumor assessment (including 6 NSCLC patients and 4 CRC patients). Most patients had received 3 or more prior anticancer regimens before entering the study (12 of 17 patients, 71%). The following treatment-related adverse events were reported in >10% of patients: diarrhea, nausea, increased AST, vomiting, fatigue, increased ALT, increased creatinine, abdominal distension, abdominal pain, increased ALP, anemia, decreased appetite, dehydration, dry mouth, dysgeusia, dyspnea, QT prolongation, hypomagnesemia, and rash. Grade 3 events included fatigue, decreased appetite, and dyspnea (1 patient each). Across all dose levels evaluated, 3 of 6 NSCLC patients and 1 of 4 CRC patients achieved PR antitumor activity ( et al., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 2019).
[0253] GDC-6036. GDC-6036 for KRAS G12C The specificity and mechanism of action of KRAS G12C Potent and irreversible inhibition of KRAS is expected to achieve a broad therapeutic index, maximizing anti-tumor activity while minimizing treatment-related toxicity. G12C Specific treatments may be available for KRAS-positive cancers G12C Provide more tolerable and effective treatment options for patients with advanced cancer.
[0254] In vitro and in vivo pharmacology studies have shown that GDC-6036 is a KRAS G12C A highly potent and selective covalent inhibitor of KRAS G12C Growth inhibition of positive cancer cell lines was selective for KRAS G12C The mechanism of action of GDC-6036 showed that in addition to KRAS target genes (such as DUSP6 and SPRY4), downstream MAPK pathway components (such as phosphorylated (p)ERK and pS6) were also inhibited and G12C Induction of apoptosis was observed in 42 positive cancer cell lines. In addition, GDC-6036 has potent single agent activity and is effective in KRAS G12C GDC-6036 inhibited tumor growth in multiple nonclinical xenograft models of KRAS-positive lung tumors. These in vitro and in vivo pharmacology studies support the use of GDC-6036 in the treatment of locally advanced or metastatic KRAS-positive lung tumors. G12C Patients with positive solid tumors.
[0255] Results from nonclinical toxicology studies completed to date provide a robust characterization of the toxicity profile of GDC-6036 and support administration of GDC-6036 in cancer patients. Comprehensive nonclinical toxicity studies were completed to evaluate the potential single and repeated dose oral toxicity, genotoxicity, phototoxicity, and safety pharmacology of GDC-6036. G12C The mutation is not present in healthy animals, so there is no KRAS G12C Pharmacologically relevant nonclinical species of inhibition.
[0256] Early Phase I clinical data from an ongoing study of AMG 510 and MRTX849 as single agents suggest that KRAS G12CThe inhibitors are well tolerated and have good antitumor activity in patients with metastatic NSCLC and CRC (Janne et al., 2019; Hong et al. New Eng J Med 2020; 383: 1207-17). However, there is still a great unmet need to use such inhibitors as single agents in NSCLC and CRC to improve the antitumor activity and durability reported in NSCLC and CRC, while importantly maintaining their tolerable safety profile.
[0257] Rationale for combination therapy. Without being bound by any particular theory, and based on a mechanistic understanding of the RTK-RAS-MAPK pathway, it is hypothesized that RAS / MAPK and PI3K / AKT are intricately interconnected signaling pathways that are often dysregulated in human cancers. Not only do these two pathways share common upstream signaling inputs, but they can also play compensatory roles when one or the other is inhibited by targeted therapy. Recent studies have also identified that when tumors become clinically resistant to KRASG12C inhibitors, key PI3K pathway components (including PIK3CA and PTEN) are genetically altered (Awad et al. 2021; Zhao et al. 2021), suggesting that activation of the PI3K signaling pathway may serve as a resistance mechanism to KRAS G12C inhibitors. Therefore, it may be necessary to simultaneously block both the RAS / MAPK and PI3K / AKT pathways to maximize clinical benefit. The combination of GDC 6036, a highly mutant-selective KRAS G12C inhibitor, and inariliximab, a PI3Kα isoform-selective inhibitor, may provide a better therapeutic window based on single-agent safety profiles and selectivity against oncogenic targets.
[0258] Multiple nonclinical studies have shown that the combination of KRAS G12C inhibitors with PI3K inhibitors can exhibit broad synergistic effects in a variety of in vitro and in vivo models, most of which do not carry dysregulated changes in PI3K pathway components (Misale et al. 2015; Canon et al. 2019; Lou et al. 2019). Mechanistically, the combination of KRAS G12C and PI3K inhibitors can simultaneously downregulate both phospho-AKT and phospho-S6RP, resulting in more reliable induction of cell death and inhibition of proliferation compared to KRAS G12C inhibitors alone (Misale et al. 2018). Consistent with these observations, nonclinical data for the combination of GDC-6036 with inaricep (Example 1) also showed synergistic effects in KRAS G12C-positive cell lines and multiple xenograft mouse models with greater tumor reduction than using either treatment alone.
[0259] The starting dose of inarliseb combined with GDC-6036 will be 6 mg PO QD in each 21-day cycle. The combination of GDC-6036 and inarliseb is expected to have acceptable tolerability. Potential overlapping toxicities include GI toxicity and oral mucosal irritation and are expected to be monitored and managed with supportive care and possible dose adjustments.
[0260] Patients will have locally advanced, recurrent or metastatic incurable solid tumors that carry a KRAS G12C mutation and have progressed after at least one available standard therapy; or for whom standard therapy has proven ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of the investigational agent is the accepted standard of care. In addition, patients may have previously received KRAS G12C inhibitor therapy.
[0261] Biomarkers. This study will identify and / or evaluate biomarkers that predict response to GDC-6036 as a single agent or in combination with a PI3K inhibitor (i.e., predictive biomarkers), biomarkers that serve as surrogates of early activity, biomarkers that correlate with progression to a more severe disease state (i.e., prognostic biomarkers), biomarkers that correlate with response to KRAS G12C Biomarkers associated with acquired resistance to inhibitors (e.g., GDC-6036), biomarkers associated with susceptibility to adverse events or biomarkers that can lead to improved adverse event monitoring or research (i.e., safety biomarkers), biomarkers that can provide evidence of the activity of the combination of GDC-6036 and inaricep (i.e., pharmacodynamic [PD] biomarkers), or biomarkers that can increase knowledge and understanding of disease biology and drug safety. Corresponding biomarker endpoints include the relationship between exploratory biomarkers in blood, plasma, and tumor tissue and safety, PK, activity, or other biomarker endpoints.
[0262] Patients will be screened for up to 28 days, followed by a treatment period and a safety follow-up period during which patients will be followed for safety outcomes until a treatment-specific period after their last dose of study drug or until they receive another anticancer therapy, whichever occurs first.
[0263] Patients may continue treatment with GDC-6036 in the absence of unacceptable toxicity and clear disease progression as determined by the investigator.
[0264] All patients will be closely monitored for adverse events throughout the study and during the treatment-specific period after the last dose of study treatment or until the initiation of another anticancer therapy, whichever occurs first. Adverse events will be graded according to NCI CTCAE v5.0.
[0265] Inarliside is a selective inhibitor of the class I PI3Kα isoform (p110α). 2 Phosphorylation to PIP 3 , inaricep reduces the activation of downstream pathway effectors including AKT, PRAS40, and S6RP, which may serve as PD biomarkers for treatment with GDC-6036 and inaricep.
[0266] KRas from tissue and circulating tumor DNA assessment G12C Mutation status. Approximately 12% of NSCLC, 4% of CRC, 2% of pancreatic cancer, and many other solid tumors (prevalence ≤ 4% each) carry KRas G12C GDC-6036 is a potent and highly selective inhibitor that targets KRas G12C , but does not target KRAS, wild-type KRAS, or other mutations in other members of the RAS family. G12C Patients with tumors that harbor KRAS mutations are eligible for administration of the combination therapies described herein. KRAS mutation status can be used CDx (F1CDx) assay (a broad companion diagnostic (CDx) assay approved by the U.S. Food and Drug Administration (FDA)), Liquid CDx (F1L CDx) assay and other FDA-approved (FDA 2020) or fully validated laboratory-developed tests performed in a Clinical Laboratory Improvement Act Amendments (CLIA) validated or equivalently certified laboratory. G12C Mutation is an early event (Jamal-Hanjani et al., N Engl J Med 2017;376:2109-21), suggesting that analysis of archival tissues may be a promising strategy for selecting KRas G12C The study is an adequate alternative for GDC-6036 treatment in patients with HER2-positive tumors.
[0267] Pharmacodynamic pathway regulation. GDC-6036 is a KRas G12C Inhibitors that inhibit KRas G12C Alkylation of GDC-6036 inhibits downstream MAPK signaling, thereby locking it in its inactive GDP-bound state. G12CThe level of alkylation and the extent of MAPK pathway inhibition correlate with response to GDC-6036. Pre-treatment and on-treatment tumor tissue collection will enable assessment of the relevance of MAPK pathway inhibition and anti-tumor activity to GDC-6036 treatment. The extent of MAPK pathway inhibition can be assessed using RNA analysis of MAPK target genes (e.g., DUSP6, SPRY4) or immunohistochemistry (IHC) analysis of phosphorylated downstream markers (e.g., pERK, pS6). In addition, on-treatment tumor tissue biopsies can enable direct assessment of the effects of GDC-6036 on KRas G12C Assessment of these PD biomarkers may inform future dose selection.
[0268] Sequencing of genes associated with resistance to GDC-6036. DNA sequencing technologies, such as targeted next generation sequencing (NGS) and whole exome sequencing, can provide unique opportunities to identify biomarkers of response and / or resistance to GDC-6036. Sequencing of cancer-related genes may lead to the identification of de novo and acquired mechanisms of resistance to GDC-6036.
[0269] Protein, RNA, and DNA analysis. In addition to mutational activation of proteins, expression levels of RNA or changes in DNA may also modulate the activity of signaling pathways. RNA profiling of tumors will allow for intrinsic subtype classification of patients enrolled in the study. Analysis of potential associations between subtypes and patient outcomes may identify subpopulations of patients most likely to respond to GDC-6036.
[0270] Plasma samples for somatic tumor mutation analysis and other biomarkers. There is growing evidence that cell-free DNA obtained from blood samples of cancer patients contains ctDNA, which represents the DNA and mutational status of tumor cells (Diehl et al., 2008; Maheswaran et al., 2008). Assays have been validated to detect cancer-associated mutations (e.g., KRAS) in plasma. The results of these assays may correlate with the mutational status determined by analysis of tumor samples. The use of ctDNA to monitor response to therapy is an area of great interest and may allow for the use of early, non-invasive, and quantifiable methods in clinical settings to identify candidates for specific therapies and monitor the mutational status of cancer over time (Wan et al., Nat Rev Cancer 2017; 17: 223-38). Analysis of ctDNA collected at different times during study treatment and after progression on GDC-6036 may help identify response mechanisms and acquired resistance to study therapy.
[0271] Blood samples for next generation sequencing. Next generation sequencing (NGS) technology can generate a large amount of sequencing data. Due to the tumorigenesis process, tumor DNA may contain both reported and unreported chromosomal changes. In order to help control sequencing calls in previously unreported genomic changes, a pre-dose blood sample will be collected to determine whether the change is somatic.
[0272] Inclusion Criteria. Patients must meet the following criteria for study entry:
[0273] Age ≥ 18 years;
[0274] ●Evaluable or measurable disease according to RECIST v1.1;
[0275] Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
[0276] ●Life expectancy ≥ 12 weeks;
[0277] ● Adequate blood and organ function within 14 days prior to starting study treatment, as determined by
[0278] The following are defined:
[0279] ○Absolute neutrophil count ≥1200 / μL;
[0280] ○Hemoglobin ≥9 g / dL;
[0281] ○ Platelet count ≥100,000 / μL;
[0282] ○Total bilirubin ≤1.5×ULN;
[0283] ○ Serum albumin ≥2.5 g / dL;
[0284] ○AST and ALT ≤ 2.5 × ULN, except in the following cases:
[0285] ■ Patients with documented liver metastases may have AST and / or ALT ≤5.0×ULN.
[0286] ○ Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL / min based on Cockcroft-Gault estimated glomerular filtration rate:
[0287] (140-age)×(weight in kg)×(0.85 if female)
[0288] 72×(serum creatinine, in mg / dL)
[0289] ●For women of childbearing age: agree to remain abstinent (avoid heterosexual intercourse) or use contraception, and agree not to donate eggs;
[0290] ● For men who have not been surgically sterilized: agree to remain abstinent (avoid heterosexual intercourse) or use contraception and agree not to donate sperm;
[0291] ● Confirmation of biomarker qualification: Valid results from central blood testing or local blood or tumor tissue testing documenting the presence of the KRasG12C mutation (e.g., a validated polymerase chain reaction (PCR)-based assay or NGS assay performed in a CLIA or equivalent certified laboratory).
[0292] Additional inclusion criteria
[0293] ● Locally advanced, recurrent or metastatic incurable malignancy with histological documentation.
[0294] ○ Disease progression after at least one available standard therapy; or standard therapy has proven ineffective or intolerant; or clinical trials of investigational agents are the accepted standard of care
[0295] Fasting blood glucose ≤140 mg / dL and glycosylated hemoglobin (HbA1c) <7 percent
[0296] ●Patients may have received prior treatment with a KRasG12C-specific inhibitor.
[0297] ● Locally advanced, recurrent, or metastatic incurable NSCLC with histological documentation (may include single-agent or combination therapy with an investigational or approved PD-L1 / PD-1 inhibitor)
[0298] General Exclusion Criteria. Patients meeting any of the following criteria were excluded:
[0299] ●Unable or unwilling to swallow pills;
[0300] ●Unable to comply with study and follow-up procedures;
[0301] ● Malabsorption syndrome or other conditions that interfere with intestinal absorption;
[0302] ●Known and untreated or active central nervous system (CNS) metastases;
[0303] Patients with a history of treated CNS metastases if they meet all of the following criteria:
[0304] ○ Measurable or assessable disease outside the CNS;
[0305] ○ No history of intracranial hemorrhage or spinal cord hemorrhage;
[0306] ○ No ongoing requirement for corticosteroids to treat CNS metastases, corticosteroids discontinued ≥2 weeks prior to administration of an agent described herein, and no ongoing symptoms due to CNS metastases;
[0307] ○ No stereotactic radiation within 7 days before Day 1 of Cycle 1 or whole brain radiation within 14 days;
[0308] ○ No clinical evidence of interim progression between completion of CNS-directed therapy and screening imaging study;
[0309] ● Leptomeningeal disease or carcinomatous meningitis;
[0310] ● Uncontrolled chest pain requiring repeated drainage procedures (every two weeks or more frequently)
[0311] membranous effusion, pericardial effusion, or ascites;
[0312] ○ If the patient has fully recovered from surgery, is hemodynamically stable, and has improved symptoms, an indwelling pleural or peritoneal catheter may be permitted;
[0313] Any active infection that could affect the patient's safety or serious infection requiring IV antibiotics within 7 days prior to Day 1 of Cycle 1;
[0314] A history of clinically significant liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis;
[0315] ●Known HIV infection;
[0316] ●Uncontrolled hypercalcemia (>1.5 mmol / L ionized calcium or calcium >12 mg / dL or corrected serum calcium ≥ULN) or symptomatic hypercalcemia requiring continued bisphosphonate therapy or denosumab;
[0317] ●Significant injury or major surgery within 4 weeks before Day 1 of Cycle 1;
[0318] ●Patients with chronic diarrhea, short bowel syndrome or major upper gastrointestinal surgery (including gastrectomy), a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), or any active intestinal inflammation (including diverticulitis);
[0319] Treatment with chemotherapy, immunotherapy, or biological therapy as anticancer therapy within 3 weeks prior to administration of an agent described herein, or treatment with endocrine therapy as anticancer therapy within 2 weeks prior to administration of an agent described herein, except in the following cases:
[0320] ○ Hormonal therapy using gonadotropin-releasing hormone (GnRH) agonists or antagonists for endocrine-sensitive cancers (e.g., prostate cancer, endometrial cancer, hormone receptor-positive breast cancer);
[0321] ○ Regulatory-approved kinase inhibitors may be used up to 2 weeks prior to the start of study treatment;
[0322] o Treatment with study agent within 3 weeks or five half-lives prior to administration of an agent described herein, whichever is shorter.
[0323] Radiation therapy (except palliative radiation to bone metastases and radiation to CNS metastases) as cancer therapy within 4 weeks prior to administration of an agent described herein;
[0324] ● Palliative radiotherapy for bone metastases within 2 weeks prior to GDC-6036 administration;
[0325] ●Unresolved adverse events from previous anticancer therapy;
[0326] ●History of other malignant tumors within 5 years before screening;
[0327] A history of or active clinically significant cardiovascular dysfunction, including:
[0328] ○ History of stroke or transient ischemic attack within 6 months prior to administration of the agents described herein;
[0329] ○ History of myocardial infarction within 6 months prior to administration of the agents described herein;
[0330] ○New York Heart Association Class III or IV heart disease or congestive heart failure requiring medication
[0331] ○ Uncontrolled arrhythmias, history of ventricular arrhythmias requiring medication, or active ventricular arrhythmias;
[0332] ○ Coronary heart disease with symptoms or unstable angina;
[0333] ○ Congenital long QT syndrome or QT interval corrected by using Fridericia formula (QTcF) > 470 ms;
[0334] ○Currently treated with medications known to prolong the QT interval;
[0335] ●Pregnant or breastfeeding, or intending to become pregnant during the study or within 6 months after the last dose of GDC-6036; or
[0336] A history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active lung inflammation on chest computed tomography (CT) scan;
[0337] Other exclusion criteria
[0338] ● Type 1 and type 2 diabetes requiring antihyperglycemic medications
[0339] Any concurrent ocular or intraocular condition (e.g., cataracts or diabetic retinopathy) that, in the opinion of the investigator and / or study ophthalmologist, requires medical or surgical intervention during the study to prevent or treat vision loss caused by that condition
[0340] Active inflammatory (such as uveitis or vitritis) or infectious (such as conjunctivitis, keratitis, scleritis, or endophthalmitis) disease in either eye or a history of idiopathic or autoimmune-related uveitis in either eye
[0341] ● Patients who need daily oxygen supply
[0342] Patients with a history of active inflammatory disease (eg, Crohn's disease or ulcerative colitis) or any active intestinal inflammation (including diverticulitis), including those currently receiving immunosuppressants (eg, sulfasalazine), were considered to have active disease and were therefore ineligible.
[0343] ●A history of prior significant toxicity related to another PI3K or mTOR inhibitor requiring discontinuation of treatment
[0344] Study therapeutic formulation, packaging and handling.
[0345] GDC-6036 will be available as an active pharmaceutical ingredient (API) powder-capsule (PIC) formulation in three strengths: 5 mg, 25 mg and 100 mg (free base equivalent). GDC-6036 drug product should be stored at or below 86°F (30°C) and protected from moisture.
[0346] For the GDC-6036 dose to be administered at home, the patient should be assigned a sufficient number of capsules or tablets to last until the next visit or to maintain a cycle. Unless the patient goes to the clinic for treatment, the patient will self-administer GDC-6036 as provided herein. Unless otherwise indicated, the patient should take GDC-6036 at approximately the same time every day. The patient will be instructed to take the number and specifications of capsules or tablets according to the dosage level and schedule specified by the patient.
[0347] Unless otherwise indicated, GDC-6036 should be taken on an empty stomach, i.e., food should be avoided for at least 2 hours before and 1 hour after the dose. There is no restriction on drinking water. It is important that GDC-6036 capsules or tablets be swallowed whole (without chewing) with at least 240 mL (8 fluid ounces) of water. If the patient misses any dose of GDC-6036 or spits out a capsule or tablet, the patient should be instructed to skip the dose and resume dosing at the next scheduled dose. Missed doses will not be made up.
[0348] Inarliseb will be provided by the trial sponsor as tablets in two strengths: 3 mg and 9 mg. Inarliseb will be administered QD PO starting at 6 mg in a 21-day cycle and will not exceed the single-agent MTD of 9 mg QD. Inarliseb can be administered concurrently with GDC-6036 with a few sips of water. Patients will self-administer inarliseb unless it is administered in the clinic on study visit days.
[0349] Unless otherwise instructed, patients should take inarliseb at approximately the same time each day without regard for food. If a patient misses any dose of inarliseb (not taken within 6 hours of the scheduled dosing time) or spits out a tablet, the patient should skip that dose, record it, and resume dosing at the next scheduled dose.
[0350] Concomitant therapy. Concomitant therapy consists of any medication other than the agents described herein (e.g., prescription drugs, over-the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a patient from 7 days prior to the first administration of at least one agent described herein to the last administration of at least one agent described herein.
[0351] Permitted Therapies. Patients may take (a) antiepileptic drugs or warfarin; (b) oral contraceptives or other permitted maintenance therapies as specified in the eligibility criteria; (c) antiemetics and antidiarrheals should not be administered prophylactically prior to initiation of study drug treatment; (d) analgesics; (e) bisphosphonates and denosumab therapy for bone metastases or osteopenia or osteoporosis; or multivitamins, calcium, and vitamin C, D, and E supplements are permitted.
[0352] Prophylactic Therapy. Drugs that are given prophylactically due to effects associated with CYP enzymes and GDC-6036 include, for example: (1) strong / moderate CYP3A4 inhibitors, including, but not limited to, the following: atazanavir, ritonavir, indinavir, nelfinavir, saquinavir, clarithromycin, telithromycin, erythromycin, troleandomycin, fluconazole, itraconazole, ketoconazole, voriconazole, posaconazole, aprepitant, conivaptan, fluvoxamine, diltiazem, nefazodone, mibefradil, verapamil, and grapefruit juice or grapefruit supplements; (2) strong / moderate CYP3A4 inducers, including, but not limited to, the following: rifampicin, carbamazepine, phenytoin, oxcarbazepine, phenobarbital, efavirenz, nevirapine, etravirine, modafinil, hyperforin (St. John's wort), and cyproterone acetate. Full dose oral or parenteral anticoagulants were used for therapeutic purposes as long as INR and / or aPTT were within therapeutic limits (per institutional criteria) within 14 days prior to administration of any agent described herein and the patient had been receiving a stable dose of anticoagulant for ≥1 week prior to initiation of study treatment. The medication list is not intended to be comprehensive.
[0353] Coumadin is strongly discouraged during therapy. Warfarin). If the patient requires anticoagulant therapy, low molecular weight heparin is recommended instead of coumadin when clinically feasible. If there is no clinically feasible alternative to coumadin, INR and prothrombin time must be monitored frequently.
[0354] Prohibited Therapies. The following concomitant therapies are prohibited during and for at least 7 days prior to the first administration of an agent described herein:
[0355] ● Investigational therapy within 3 weeks or five half-lives prior to the first administration of an agent described herein, whichever is shorter;
[0356] ● Concomitant therapy intended to treat cancer, whether FDA-approved or experimental, including chemotherapy, radiation therapy, immunotherapy, biological therapy, traditional Chinese medicine, or hormonal therapy, except for the following:
[0357] ○ Hormonal therapy using gonadotropin-releasing hormone (GnRH) agonists or antagonists for endocrine-sensitive cancers (e.g., prostate cancer, endometrial cancer, hormone receptor-positive breast cancer);
[0358] ○ Hormone replacement therapy or oral contraceptives.
[0359] ●Radiotherapy for clear progressive disease, excluding new brain metastases in the setting of a systemic response: who have demonstrated systemic disease control (defined as clinical benefit)
[0360] Patients who have achieved a PR, CR, or SD lasting ≥3 months) but have developed brain metastases that are amenable to radiation therapy will be allowed to continue therapy with GDC-6036 during the study until they experience systemic progression of their disease and / or further progression in the brain (based on investigator assessment);
[0361] Quinidine or other antiarrhythmic drugs;
[0362] ●Start 7 days before day 1 of cycle 1 or increase hematopoietic colony stimulating factor (CSF;
[0363] e.g. granulocyte CSF; filgrastim, granulocyte / macrophage CSF; sargramostim, pegfilgrastim, erythropoietin, darbepoietin, and thrombopoietin)
[0364] Warning risks
[0365] Strong CYP3A4 inhibitors, including but not limited to the following: atazanavir, ritonavir, indinavir, nelfinavir, saquinavir, clarithromycin, troleandomycin, itraconazole, ketoconazole, voriconazole, posaconazole, conivaptan, diltiazem, nefazodone, and mibefradil
[0366] Strong CYP3A4 inducers, including but not limited to the following: rifampin, carbamazepine, phenytoin, oxcarbazepine, phenobarbital, nevirapine, hypericum (St. John's wort), and cyproterone acetate
[0367] P-gp inhibitors, including but not limited to ritonavir, cyclosporine, verapamil, erythromycin, ketoconazole, itraconazole, quinidine, elacridar, and valspodar
[0368] BCRP inhibitors, including but not limited to curcumin, cyclosporine A, and eltrombopag
[0369] Risks associated with GDC-6036. Administration of GDC-6036 is associated with diarrhea, nausea, vomiting, and minimal to mild transaminase elevations. Other potential risks include oral mucosal irritation.
[0370] Risks associated with inarliside. Based on the class effects established with PI3K and mTOR inhibitors in cancer patients, as well as nonclinical data and clinical experience with inarliside, hyperglycemia, stomatitis / oral mucositis, rash, diarrhea / colitis, and pneumonitis are safety concerns with the use of inarliside. Given that these adverse events may require dose interruption and / or dose reduction, or may result in life-threatening situations, close monitoring and robust risk mitigation strategies are warranted.
[0371] . Hyperglycemia - Effects on glucose and / or insulin metabolism are known effects of PI3K inhibitors. In toxicology studies in rats and dogs, glucose increases were observed at all doses tested and appeared to be dose-dependent. Hyperglycemia has been reported in patients treated with inarliside and is an identified risk for inarliside. Therefore, patients with type I or type II diabetes who require medication and have elevated fasting blood glucose at baseline (fasting blood glucose >140 mg / dL or HbA 1c Patients with a ≥7% (≥7%) will be excluded. Fasting blood glucose levels will be assessed at baseline and will be monitored. Patients should be advised to report symptoms associated with hyperglycemia, such as thirst, polyuria, polyphagia, blurred vision, or symptoms associated with acidosis, such as shortness of breath or weakness, confusion, fatigue, headache, or drowsiness. Patients should be given metformin as a first-line agent for the treatment of hyperglycemia.
[0372] Stomatitis and oral mucositis. Treatment-related stomatitis / oral mucositis has been reported with the use of inarisept. Patients should be advised to report symptoms promptly. Intervention should be initiated at the earliest sign of oral mucosal inflammation. If available topically, an alcohol-free dexamethasone-combined mouthwash (0.5 mg dexamethasone in 5 mL) is recommended for the prevention or treatment of stomatitis / mucositis. Patients may initiate use concurrently with study treatment 4 times daily for 8 weeks (rinse 10 mL for 2 minutes and expectorate), and / or reactively at the first onset of symptoms, as per the SWISH study (Rugo et al. 2017). Other mouthwash formulations (e.g., combinations of local anesthetics, antihistamines, corticosteroids, antacids, antifungals, and / or antibiotics) or topical corticosteroids (e.g., triamcinolone acetonide 0.05%-0.5%, fluocinolone acetonide 0.025%-0.05%, clobetasol propionate 0.025%) may be implemented. Patients should avoid products containing alcohol, hydrogen peroxide, iodine, or thyme, as they may worsen the condition. They should also avoid using irritating mouthwashes (such as ). The diet should be modified (eg, avoiding spicy foods).
[0373] Gastrointestinal toxicity. In the 4-week inarise toxicology study in dogs, GI inflammation was observed. Patients with inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) and active intestinal inflammation (e.g., diverticulitis) will be excluded. GI effects will be closely monitored by interval history and physical examination. The appearance of clinically significant changes in abdominal pain, nausea, vomiting, stool (e.g., diarrhea, bloody stools) may require more frequent monitoring, and if symptoms interfere with normal function, the study drug may be discontinued. Infectious (e.g., Clostridium difficile, Enterobacter and cytomegalovirus) or inflammatory (e.g., inflammatory colitis) causes of diarrhea should be clinically evaluated.
[0374] Dermatologic Disorders. Treatment-related rashes have been reported in clinical studies with other PI3K inhibitors and typically present as maculopapular rashes with or without pruritus. Rash and other dermatologic events should be closely monitored and managed according to standard of care.
[0375] Other potential risks of using Inaricep:
[0376] Pulmonary inflammation / pneumonitis. In a 4-week toxicology study of inaricep in dogs, pulmonary inflammation was observed at the highest dose tested. This finding was only observed at a dose considered intolerant in this species. Interstitial lung inflammation / pneumonitis has been observed in clinical studies with other PI3K inhibitors.
[0377] Immunosuppressive Effects. Immunosuppression and increased risk of infection are known to be associated with marketed PI3K / mTOR pathway inhibitors. Toxicology studies have demonstrated decreases in reticulocyte, leukocyte, and absolute lymphocyte counts in animals treated with inaricep. Patients who are immunocompromised due to HIV or receiving immunosuppressive therapy will be excluded. Patients will be monitored regularly for changes in circulating blood counts, including white blood cell differential counts, and should be monitored for fever and signs of infection.
[0378] Reproductive Effects. Potential adverse effects on male reproductive function, including focal condensation of seminiferous tubule contents and multinucleated spermatocytes in the testis and epithelial cell degeneration / necrosis in the epididymis, were observed in one or more dogs during a 4-week repeat-dose toxicity study. Focal condensation of seminiferous tubule contents persisted in one animal at the end of the 4-week recovery period.
[0379] Ocular toxicity. In a 4-week toxicology study in rats, lens degeneration was observed in the highest inarlised dose group (10 mg / kg; 4 of 30 rats). This finding is characterized by minimal to mild lens fiber swelling, lens fiber separation, and / or subcapsular protein material accumulation. It is unclear whether this lens finding is a direct effect of inarlised or an indirect effect secondary to significant hyperglycemia in this dose group. In rats at lower doses, inarlised-related ocular findings were not observed. In dogs, ocular-related findings include inflammation and lens fiber swelling. In dogs administered inarlised (treated with 1.5 mg / kg and reduced to 1.0 mg / kg) for 3 months, ocular inflammation was limited to local, minimal neutrophil infiltration in the limbal junctional stroma. In a 4-week study in dogs, neutrophil infiltration, mild endophthalmitis, and low-grade uveitis were observed in the highest dose group (treated with 5 mg / kg and reduced to 3 mg / kg) (the dose was considered intolerant). These findings are reversible and may be part of a systemic generalized inflammatory disorder. In a 3-month toxicity study, in dogs administered ≥0.3 mg / kg of inarlised, bilateral, reversible, and very slight swelling of the fibers at the equatorial region of the lens was observed in one male and one female dog at 0.3 mg / kg and one male and one female dog treated with 1.5 mg / kg and reduced to 1.0 mg / kg. Patients with any concurrent ocular or intraocular disorders (such as cataracts or diabetic retinopathy) that will require medical or surgical intervention will be excluded. In addition, patients with active uveitis or vitritis, a history of uveitis, or an active infectious process in the eye will also be excluded.
[0380] Treatment Interruptions. If GDC-6036 is discontinued for >21 days from previous study treatment due to toxicity, study treatment should not be restarted. GDC-6036 may be withheld for up to 21 days for unexpected intercurrent medical events not related to study treatment toxicity or disease progression.
[0381] Adverse events. An adverse event as defined herein refers to any unfortunate medical event in a clinical study subject to which the agents described herein are administered in the combination therapy described herein, regardless of causal attribution. The terms "serious" and "critical" are not synonymous. Severity refers to the intensity of the adverse event (e.g., graded as mild, moderate, or severe, or according to the NCICTCAE); the event itself may have relatively minor medical significance (such as a severe headache without any further findings)).
[0382] Adverse events to be monitored include nausea, vomiting, diarrhea, stomatitis, mucositis, hepatitis or ALT or AST elevation, bilirubin elevation or clinical jaundice, systemic lupus erythematosus, nephritis, events suggestive of hypersensitivity, infusion-mediated reactions, CRS, influenza-like illness and systemic inflammatory response syndrome, atrial fibrillation, myocarditis, pericarditis, vasculitis, myositis, uveitis, retinitis, optic neuritis, autoimmune hemolytic anemia, Stevens-Johnson syndrome, bullous dermatitis, and toxic epidermal necrolysis.
[0383] Adverse events of special interest specific to inaricep are as follows:
[0384] ≥Grade 3 hyperglycemia
[0385] Rash ≥ Grade 3
[0386] Grade ≥3 diarrhea
[0387] Grade ≥2 pneumonitis
[0388] Grade ≥2 colitis or enterocolitis
[0389] ≥ Grade 3 stomatitis or mucosal inflammation
[0390] Grade ≥3 ALT or AST elevation
[0391] In the present specification and claims, unless the context requires otherwise, the words "comprise", "include" and "contain" are used in a non-exclusive sense. It is understood that the embodiments described herein include "consisting of" and / or "consisting essentially of" the embodiments. It is further understood that the expression "GDC-6036" as used herein refers to the free base compound as well as the GDC-6036-adipate salt or other pharmaceutically acceptable salts thereof.
[0392] If a range of values is provided, it is understood that each intervening value (to one-tenth of the unit of the lower limit, unless the context clearly dictates otherwise) between the upper and lower limits of the range, as well as any other specified or intervening value in the specified range, is encompassed herein. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed herein, subject to any explicitly excluded limits in the specified ranges. Where the stated range includes one or both limits, ranges excluding one or both of those included limits are also encompassed herein.
[0393] Many variations and other embodiments of the invention set forth herein will come to mind to those skilled in the art to which the present invention relates, with the benefit of the above description and the teachings presented in the associated drawings. Therefore, it should be understood that the present invention is not limited to the specific embodiments disclosed, and variations and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, these terms are used only in a general and descriptive sense and not for purposes of limitation.
Claims
1. A combination therapy comprising: (a) GDC-6036 or a pharmaceutically acceptable salt thereof; and (b) Inavolisib or a pharmaceutically acceptable salt thereof.
2. The combination therapy according to claim 1, wherein GDC-6036 is its adipate salt.
3. The combination therapy according to claim 1 or 2, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more cycles.
4. The combination therapy according to claim 3, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD on day 1 to day 21 of a dosing regimen comprising one or more 21-day cycles, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered orally in the form of a tablet or capsule.
5. The combination therapy of claim 3, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more 28-day cycles, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered orally in the form of a tablet or capsule.
6. The combination therapy according to any one of claims 1 to 5, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 50 mg to 500 mg.
7. The combination therapy according to any one of claims 1 to 6, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg or 800 mg.
8. The combination therapy according to any one of claims 1 to 6, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg or 400 mg.
9. The combination therapy according to any one of claims 1 to 6, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 200 mg.
10. The combination therapy according to any one of claims 1 to 6, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 400 mg.
11. The combination therapy according to any one of claims 1 to 10, wherein inaricep or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more cycles.
12. The combination therapy according to claim 11, wherein inaricep or a pharmaceutically acceptable salt thereof is administered QD from day 1 to day 21 of a dosing regimen comprising one or more 21-day cycles.
13. The combination therapy according to any one of claims 1 to 12, wherein inaricep or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more 28-day cycles.
14. The combination therapy according to any one of claims 1 to 13, wherein the dosing regimen includes a rest period in which one or both of GDC-6036 and inaricep are not administered.
15. The combination therapy according to any one of claims 1 to 14, wherein inaricep is administered in an amount of about 3 mg, 6 mg or 9 mg.
16. The combination therapy according to any one of claims 1 to 15, wherein inaricep is administered in an amount of 6 mg.
17. The combination therapy according to any one of claims 1 to 15, wherein inaricep is administered in an amount of 9 mg.
18. A combination therapy according to any one of claims 1 to 17 for use in the treatment of a disease comprising KRas G12C Mutated lung cancer.
19. The combination therapy of claim 18, wherein the lung cancer is non-small cell lung cancer (NSCLC).
20. A combination therapy according to any one of claims 1 to 17 for use in the treatment of a disease comprising KRas G12C mutations in colorectal cancer (CRC).
21. The combination therapy according to any one of claims 1 to 20, wherein the patient is assessed for the presence of the KRasG12C mutation prior to administration.
22. The combination therapy according to any one of claims 1 to 21, wherein no assessment for the presence of mutant PIK3CA is performed prior to administration.
23. A method for treating a patient with KRas G12C A method for treating lung cancer in a patient with lung cancer mediated by a mutation thereof, the method comprising administering an effective amount of a combination therapy comprising: (a) GDC-6036 or a pharmaceutically acceptable salt thereof, GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more cycles; and (b) Inarice or a pharmaceutically acceptable salt thereof, inaricep or a pharmaceutically acceptable salt thereof is administered QD according to the dosing regimen comprising one or more cycles.
24. The method of claim 23, wherein the lung cancer is NSCLC.
25. The method of claim 23 or 24, wherein the lung cancer is adenocarcinoma, squamous cell lung cancer, or large cell lung cancer.
26. A method of treating cancer in a patient having a solid tumor comprising a KRasG12C mutation, The method comprises administering an effective amount of a combination therapy comprising: (a) GDC-6036 or a pharmaceutically acceptable salt thereof, GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more cycles; and (b) Inarice or a pharmaceutically acceptable salt thereof, inaricep or a pharmaceutically acceptable salt thereof is administered QD according to the dosing regimen comprising one or more cycles.
27. The method of claim 26, wherein the solid tumor is colorectal cancer (CRC).
28. The method according to any one of claims 23 to 27, further comprising: (a) determining the absence or presence of a KRasG12C mutation in a sample taken from a patient with a suspected diagnosis of cancer; as well as (b) administering to the patient a combination therapy as described herein, said combination therapy comprising effective amounts of GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep.
29. A method of treating a patient having a histologically indeterminate cancer comprising a KRasG12C mutation, the method comprising administering an effective amount of a combination therapy comprising: (i) determining the absence or presence of a KRasG12C mutation in a sample taken from a patient with a suspected diagnosis of cancer; and (ii) where the patient sample comprises the KRasG12C mutation, administering an effective amount of a combination therapy comprising: (a) GDC-6036 or a pharmaceutically acceptable salt thereof, GDC-6036 or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more cycles; and (b) Inarice or a pharmaceutically acceptable salt thereof, inaricep or a pharmaceutically acceptable salt thereof is administered QD according to a dosing regimen comprising one or more cycles.
30. The method of any one of claims 23 to 29, wherein the dosing regimen comprises one or more 21 day cycles.
31. The method of claim 30, wherein the dosing regimen includes a rest period in which one or both of GDC-6036 and inaricep are not administered.
32. The method of any one of claims 23 to 29, wherein the dosing regimen comprises one or more 28-day cycles.
33. The combination therapy according to any one of claims 23 to 32, wherein GDC-6036 is its adipate salt.
34. The method according to any one of claims 23 to 33, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered orally in the form of a tablet or capsule.
35. The method of any one of claims 23 to 34, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 50 mg to 500 mg.
36. The method of any one of claims 23 to 35, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg or 800 mg.
37. The method of any one of claims 23 to 36, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 100 mg, 200 mg or 400 mg.
38. The method of any one of claims 23 to 37, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 200 mg.
39. The method of any one of claims 23 to 37, wherein GDC-6036 or a pharmaceutically acceptable salt thereof is administered in an amount of about 400 mg.
40. The method of any one of claims 23 to 39, wherein inaricep is administered in an amount of about 3 mg, 6 mg or 9 mg.
41. The method of any one of claims 23 to 40, wherein inaricep is administered in an amount of 6 mg.
42. The method of any one of claims 23 to 40, wherein inaricep is administered in an amount of 9 mg.
43. The method of any one of claims 23 to 42, wherein the patient is not assessed for the presence of mutant PIK3CA prior to administration.
44. Use of a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep or a pharmaceutically acceptable salt thereof for treating lung cancer, CRC or pancreatic cancer as described herein.
45. The use according to claim 44, wherein the cancer is lung cancer or CRC, and further comprising a dosing regimen comprising: (i) administering GDC-6036 or a pharmaceutically acceptable salt thereof QD according to a dosing regimen comprising one or more cycles; and (ii) administering inaricep QD according to said dosing regimen comprising one or more cycles.
46. Use of a combination therapy comprising GDC-6036 or a pharmaceutically acceptable salt thereof and inaricep or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of lung cancer, CRC or pancreatic cancer.
47. The use according to claim 46, wherein the cancer is lung cancer or CRC, and further comprising a dosing regimen comprising: (i) administering GDC-6036 or a pharmaceutically acceptable salt thereof QD according to a dosing regimen comprising one or more cycles; and (ii) administering inaricep QD according to said dosing regimen comprising one or more cycles.
48. The use according to claim 46, wherein the cancer is CRC, and further comprising a dosing regimen comprising: (i) administering GDC-6036 or a pharmaceutically acceptable salt thereof QD according to a dosing regimen comprising one or more 21-day cycles; and (ii) administering inaricep according to a dosing regimen comprising one or more 21-day cycles.
49. The use according to any one of claims 44 to 48, wherein the dosing regimen comprises one or more 21 day cycles.
50. The use according to any one of claims 44 to 48, wherein the dosing regimen comprises one or more 28-day cycles.
